[go: up one dir, main page]

WO2020097116A1 - Compositions et méthodes de culture de cellules de levure - Google Patents

Compositions et méthodes de culture de cellules de levure Download PDF

Info

Publication number
WO2020097116A1
WO2020097116A1 PCT/US2019/059921 US2019059921W WO2020097116A1 WO 2020097116 A1 WO2020097116 A1 WO 2020097116A1 US 2019059921 W US2019059921 W US 2019059921W WO 2020097116 A1 WO2020097116 A1 WO 2020097116A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
medium
yeast cells
yeast
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/059921
Other languages
English (en)
Inventor
Alexandria SCHWIER
Jessica SCHMALZ
Gary D. ARONSON
Sinil Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rejuvenation Therapeutics
Original Assignee
Rejuvenation Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rejuvenation Therapeutics filed Critical Rejuvenation Therapeutics
Publication of WO2020097116A1 publication Critical patent/WO2020097116A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/18—Baker's yeast; Brewer's yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/38—Nucleosides

Definitions

  • the present disclosure relates generally to media and methods for culturing yeast cells to produce one or more NAD+-related and precursor compounds.
  • the present disclosure also relates to compositions comprising yeast ceils that produce one or more NAD+-related and precursor compounds and methods of using the compositions, which may provide benefits for the treatment and prevention of mitochondrial diseases and extending lifespan.
  • Nicotinamide adenine dinucleotide (NAD+ or NADH) has important biological functions m cellular metabolism. Decline of NAD+ levels has been attributed to the development of many diseases and conditions associated with metabolic dysfunction.
  • NAM nicotinamide
  • NR nicotinic acid
  • NAAD nicotinic acid adenine dinucleotide
  • NAMN nicotinic acid mononucleotide
  • NNMN nicotinamide mononucleotide
  • NAR nicotinic acid riboside
  • compositions comprising these yeast or extracts thereof comprising one or more of the NAD+-related and precursor compounds, which may provide benefits for the treatment and prevention of mitochondrial diseases and extending
  • a medium for culturing yeast cells comprising at least about 6 mM nicotinic acid (NA) or a salt thereof.
  • the medium comprises about 6 mM - 20 mM NA.
  • the medium further comprises nicotinamide (NAM).
  • the medium comprises at least about 6 mM NAM. In some embodiments, the medium comprises about 6 mM - 20 mM NAM.
  • a medium for culturing yeast cells comprising at least about 6 mM nicotinamide (NAM) or a salt thereof.
  • the medium comprises about 6 mM - 20 mM N AM.
  • the medium further comprises NA.
  • the medium comprises at least about 6 mM of NA.
  • the medium comprises about 6 mM - 20 mM NA.
  • the medium further comprises a flavonoid.
  • the flavonoid is fisetin, quercetin, apigenin, or iuteolin.
  • the medium comprises quercetin.
  • the medium comprises fisetin.
  • the medium further comprises a fruit or vegetable extract, a fruit or vegetable concentrate, or a fruit or vegetable powder.
  • the medium comprises further comprises piperlongumine.
  • the medium is for culturing yeast cells that are not genetically modified organisms (GMOs). In some embodiments, the medium is for culturing yeast cells that are Saccharomyces cerevisiae.
  • Also provided herein is a method of screening a yeast strain, the method comprising (a) culturing yeast ceils from a yeast strain in a medium comprising 20 mM - 60 mM
  • the method further comprises repeating step (a) and step (b) with a plurality of yeast strains.
  • the method further comprises (c) determining the concentration of one or more of nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid riboside (NAR), nicotinamide adenine dinucleotide (NAD+), nicotinic acid adenine dinucleotide (NAAD), or nicotinic acid mononucleotide (NAMN) in the yeast cells or the medium after step (a).
  • the method further comprises repeating step (c) with a plurality of yeast strains.
  • the method further comprises (d) selecting a yeast strain that grows in the medium and whose yeast cells produce one or more of NMN, NR, NAR,
  • the method further comprises (d) selecting a yeast strain that grows in the medium and whose yeast cells produce one or more of NMN, NR, NAR, NAD+, NAAD, NA, NAM, NADH, NADP+,
  • the desired level is an amount sufficient to produce a dry composition comprising an extract of the yeast cells comprising at least 1% of one or more of NMN, NR, NAR, NAD+, NAAD, or NAMN (w/w) produced by the yeast cells.
  • the desired level is an amount sufficient to produce a dr composition comprising an extract of the yeast cells comprising one or more of: (a) 0.05% - 1% NAM, (b) 0.5% - 1.2% NA, (c) 0.05% - 0.23%
  • the extract was produced by mechanically lysing the yeast ceils. In some embodiments, the extract was produced without the addition of methanol, ethanol, or hazardous chemicals. Also provided herein is a yeast cell from a yeast strain selected in a method described herein.
  • Also provided herein is a method of culturing yeast cells, the method comprising culturing yeast cells m a medium described herein. Also provided herein is a method of preparing NMN and/or NR, comprising culturing yeast cells in a medium described herein. In some embodiments, the method further comprises extracting NMN and/or NR from the yeast cells.
  • the yeast cells are a plurality of a yeast cell from a yeast strain selected in a method described herein. In some embodiments, the yeast cells are
  • yeast cells are not genetically modified organisms (GMOs).
  • the method comprises culturing the yeast cells for at least 2 hours. In some embodiments, the method comprises culturing the yeast cells for at least 30 hours. In some embodiments, the culturing comprises stirring and/or aerating the medium. In some embodiments, the culturing further comprises adding one or more of yeast nutrient, soya peptone, or a sugar after at least 2 hours of culturing. In some embodiments, the temperature of the medium is about 75° F - about 85° F during culturing.
  • the method further comprises inactivating the yeast cells.
  • the inactivating comprises sonicating, microwaving, or pasteurizing the yeast cells.
  • the method further comprises concentrating the yeast cells.
  • the concentrating comprises centrifuging or filtering the yeast cells.
  • the method does not comprise adding methanol, ethanol, or hazardous chemicals to the yeast cells or an extract thereof.
  • the method further comprises lysing the yeast cells to produce an extract.
  • the lysing is mechanical lysing.
  • the method further comprises centrifuging or filtering the extract.
  • the method further comprises freeze drying the extract.
  • compositions comprising the yeast cells produced by a method described herein, or an extract thereof, or an extract produced by a method described herein. Also provided herein is a composition comprising yeast cells or an extract thereof comprising at least 500 mM NR and/or at least 500 mM NMN. Also provided herein is a composition comprising yeast cells or an extract thereof comprising at least 0.4% NR (w/w) and/or at least 0.4% NMN (w/w). In some embodiments, the composition comprises at least 0.4% NR (w/w) and at least 0.4% NMN (w/w). In some embodiments, the yeast cells produced at least 50% of the NR and/or NMN in the composition.
  • composition comprising yeast cells or an extract thereof comprising one or more of: (a) 0.05% - 1% NAM, (b) 0.5% - 1.2% NA, (c) 0.05% - 0.23% NAD+, (d) 0.002% - 0.02% NADH, (e) 0.02% - 0.08% NADP+, (f) 0 01 % - 0.2% NADPH, (g) 0.02% - 0.07% NMN, (h) 0.01% - 0.2% NAMN, (i) 0 001 % - 0.009% NR, (j) 0.002%-0.015% NAR, (k) 0.0005%-0.004% MNA, and (3) 0.001 %- 0.02% trigonelline (w/w).
  • compositions comprising yeast cells or an extract thereof comprising a total amount of Q.1%-0.5% (w/w) of NAD+, NMN, NAMN, NR, and NAR. Also provided herein is a composition comprising yeast cells or an extract thereof comprising a total amount of 0.5% -2.25% (w/w) of NAM, NA, NAD+, NMN, NAMN, NR, and NAR.
  • the yeast cells in the composition are not genetically modified organisms (GMOs).
  • the yeast cells in the composition are Saccharomyces cerevisiae.
  • the yeast cells in the composition have been inactivated.
  • the yeast cells were inactivated by somcation, microwaving, or pasteurization.
  • the composition comprises NAD+. In some embodiments, the composition comprises at least 0.25% NAD+ (w/w). In some embodiments, the yeast cells produced at least 50% of the NAD+. In some embodiments, the composition further comprises NA, NAR, NAAD, NAMN, or combinations thereof. In some embodiments, the composition comprises at least 1% NA (w/w). In some embodiments, the composition further comprises a compound or plurality of compounds that are capable of lowering total plasma homocysteine in a subject. In some embodiments, the composition further comprises serine, vitamin Be,, vitamin E>9, and vitamin Bn. In some embodiments, the composition further comprises a f!avonoid.
  • the flavonoid is fisetin, quercetin, apigenin, and luteolin.
  • the composition comprises quercetin, fisetin, or quercetin and fisetin.
  • the composition further comprises piperlongumine, vitamin B 2 , JV-acetylcysteine, 5 ⁇ adenosylmethionine (SAM), trimethylglycine, or combinations thereof.
  • the composition further comprises a fruit or vegetable extract, a fruit or vegetable concentrate, a fruit or vegetable powder, tuna or an extract thereof, salmon or an extract thereof, bulgur or an extract thereof, barely or an extract thereof, or a combination thereof.
  • the composition is a paste or a powder. In some embodiments, the composition has been freeze dried.
  • composition comprising the
  • composition described herein and a pharmaceutically acceptable excipient.
  • a dietary supplement, food product, or medical food comprising a composition described herein or a pharmaceutical composition described herein.
  • Also provided herein is a method of modulating blood NAD+ level comprising administering to a subject an effective amount of a composition described herein, a
  • composition described herein a dietary supplement described herein, a food product described herein, or a medical food described herein.
  • a method of extending lifespan of a subject comprising administering to the subject an effective amount of a composition described herein, a pharmaceutical composition described herein, a dietary- supplement described herein, a food product described herein, or a medical food described herein.
  • a method of improving healthspan of a subject comprising administering to the subject an effective amount of a composition described herein, a
  • composition described herein a dietary supplement described herein, a food product described herein, or a medical food described herein.
  • a method of enhancing or maintaining muscle growth or performance comprising administering to a subject an effective amount of a composition described herein, a pharmaceutical composition described herein, a dietary supplement described herein, a food product described herein, or a medical food described herein.
  • a method of treating or preventing a mitochondrial disease or condition comprising administering to a subject in need thereof a therapeutically effective amount of a composition described herein, a pharmaceutical composition described herein, a dietary supplement described herein, a food product described herein, or a medical food described herein.
  • NAD+ has important functions in cellular bioenergetics and adaptive stress responses. Decreasing NAD+ levels have been associated with metabolism-related diseases, including neurodegenerative diseases, cardiovascular diseases, muscle atrophy, and age-related conditions. Maintenance of NAD+ levels is especially important for cells with higher energy demands. Therefore, molecules involved in NAD+ biosynthesis and consumption are of particular interest in modulating NAD+ level as a way to combat these diseases and conditions.
  • Nicotinamide (NAM) and nicotinic acid (NA) can be produced in large quantities; however production of NAD+ and other NAD+ precursors (such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN)) is more difficult and expensive, as well as can result in potentially toxic byproducts.
  • NAD+ and other NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN)
  • GMOs genetically modified organisms
  • NAD+ and NAD+ precursors such as NMN and NR
  • the terms“including,”“containing,” and“comprising” are used in their open, non-limiting sense. It is understood that embodiments of the invention described herein include“consisting” and/or“consisting essentially of’ embodiments.
  • the term“consists essentially of’ means excluding other materials that contribute to function, unless otherwise defined herein. Nonetheless, such other materials may be present, collectively or individually, in trace amounts.
  • beneficial or desired results include, but are not limited to: reducing the severity of or suppressing the worsening of an existing disease, symptom, or condition, alleviating a symptom and/or diminishing the extent of a symptom and/or preventing a worsening of a symptom associated with a condition, arresting the development of a disease, symptom, or condition, relieving the disease, symptom, or condition, causing regression of the disease, disorders, conditions, or symptom (in terms of severity or frequency of negative symptoms), or stopping the symptoms of the disease or condition.
  • Beneficial or desired results can also be slowing, halting, or reversing the progressive course of a disease or condition.
  • Preventing includes providing prophylaxis with respect to the occurrence or recurrence of a disease or condition in a subject that may be predisposed to the disease or condition but has not yet been diagnosed with the disease or condition.
  • the provided compositions are used to delay development of a disease or condition or to slow the progression of a disease or condition.
  • any compound recited herein may also exist as a corresponding salt, solvate or hydrate, the use of such salts, solvates or hydrates in place of or in addition to the recited compound is also encompassed by the present invention.
  • A“pharmaceutically acceptable salt” is a salt form that is non-toxic, biologically tolerable, or otherwise biologically suitable for administration to the subject. See generally Berge et al. (1977) J Pharm. Sci. 66, 1 -19. Particular pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of subjects without undue toxicity, irritation, or allergic response.
  • A“hazardous chemical” is a chemical that is categorized as a health hazard by the Globally Harmonized System of Classification and Labelling of Chemicals and/or the United States Occupational Safety and Health Administration standards.
  • dosages and weights refer to the quantity of elemental metal, not to the weight of the compound containing the metal.
  • a weight or dosage of such a mineral is specified, this refers to the weight or dosage of the particular element and not the compound which contains it, unless the context clearly implies otherwise, or unless explicitly stated otherwise.
  • NAD+ has important functions in cellular bioenergetics and adaptive stress responses. Decreasing NAD+ levels have been associated with metabolism-related diseases, including neurodegenerative diseases, cardiovascular diseases, muscle atrophy, and age-related conditions. Maintenance of NAD+ levels is especially important for cells with higher energy demands. Therefore, molecules involved in NAD+ biosynthesis and consumption are of particular interest in modulating NAD+ level as a way to combat these diseases and conditions.
  • NAD+ can be synthesized from a variety of sources.
  • Major precursors for NAD+ biosynthesis include, but are not limited to, nicotinic acid (NA), nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), nicotinamide (NAM), nicotinic acid adenine dinucleotide, nicotinic acid mononucleotide, trigonelline, 1 -methylnicotinamide (MNA) and nicotinic acid riboside ( NAR)
  • NA nicotinic acid
  • NR nicotinamide riboside
  • NR nicotinamide mononucleotide
  • NAM nicotinamide
  • MNA 1 -methylnicotinamide
  • NAR nicotinic acid riboside
  • NAD+ can be any organic compound that has a high degree of activity.
  • NA can be converted to nicotinic acid mononucleotide, and then to nicotinic acid adenine dinucleotide, which can produce NAD+ enzymatically.
  • NR and NAM can be converted to NMN which can then produce NAD+ enzymatically.
  • NAR can also be generated from NA through NMN formation and is an integral part of NAD metabolism. Kulikova et al (2015) ,/. Bio. Chern. 290, 27124.
  • NAD+ can be further converted to NADPH and NADP, another two major reagents and coenzymes in metabolism, especially in a multitude of redox reactions.
  • Nicotinic acid (NA); Nicotinamide riboside (NR); Nicotinamide mononucleotide (NMN);
  • Nicotinamide (NAM); Nicotinic acid riboside (NAR); Nicotinamide adenine dinucleotide phosphate (NADP)
  • Nicotinic acid adenine dinis eotide (NAAD); Nicotinic acid mononucleotide (NAMN); Trigonelline; l-meihylnicotinamide (MNA).
  • NAAD Nicotinic acid adenine dinis eotide
  • NAMN Nicotinic acid mononucleotide
  • MNA l-meihylnicotinamide
  • NMN is a direct precursor of NAD+.
  • NR, NAM, and NA need to be converted to NMN in order to produce NAD+.
  • NMN may be a more potent NAD+ modulator compared to the other NAD+ precursors.
  • NMN is extracellularly degraded to Nicotinamide Riboside prior to cellular active transpor uptake.
  • NMN may act as a sustained-release prodrug formulation for Nicotinamide Riboside, extending its pharmacokinetic life and pharmacodynamics activity over time. See e.g., J. Biol. Chem. 288, 25938; Social! et al . (2016) Oncotarget 7, 2968.
  • NMN can make its way through the liver intact and bloodstream into muscle and is metabolized to NAD+ within 30 minutes. Mills et al. (2016) Cell Me tab. 24, 795. And NMN was shown to be retained m the body for longer than NAM Kawamura et al (2016) J. Nutr. Sci. Vitaminol 62, 272.
  • the medium comprises nicotinic acid (NA) or a salt thereof.
  • NA nicotinic acid
  • the medium comprises at least about 1 mM NA, such as at least about 1.5 mM, 2 mM, 2.5 mM, 3 mM, 4 mM, 5 mM, 6 mM, 8 mM, 10 mM, 12 mM, 14 mM, 16 mM, or 18 mM NA.
  • the medium comprises at least about 6 mM NA.
  • the medium comprises about 1 mM - 60 mM NA, such as about 2 mM - 60 mM, 2 5 mM - 60 mM, 3 mM - 60 mM, 4 mM - 60 mM, 5 mM - 60 mM, 6 mM - 60 mM, 8 mM - 60 mM, 10 - 60 mM, 20 - 60 mM, 30 - 60 mM, or 40 - 60 mM NA.
  • the medium comprises 6 mM - 60 mM NA.
  • the medium comprises 15 mM - 20 mM NA.
  • the medium comprises about 1 mM - 20 mM NA, such as about 2 mM - 20 mM, 2, 5 mM - 20 mM, 3 mM - 20 mM, 4 mM - 20 mM, 5 mM - 20 mM, 6 mM - 20 mM, 8 mM - 20 mM, or 10 - 20 mM NA.
  • the medium comprises 6 mM - 20 mM NA.
  • the medium comprises nicotinamide (NAM) or a salt thereof.
  • NAM nicotinamide
  • the medium comprises at least about 1 mM NAM, such as at least about 1.5 mM, 2 mM, 2.5 mM, 3 mM, 4 mM, 5 mM, 6 mM, 8 mM, 10 mM, 12 mM, 14 mM, 16 mM, or 18 mM NAM.
  • the medium comprises at least about 6 mM NAM.
  • the medium comprises about 1 mM - 60 mM NANI, such as about 2 mM - 60 mM, 2, 5 mM - 60 mM, 3 mM - 60 mM, 4 mM - 60 mM, 5 mM - 60 mM, 6 mM - 60 mM, 8 mM - 60 mM, 10 - 60 mM, 20 - 60 mM, 30 - 60 mM, or 40 - 60 mM NAM.
  • NANI such as about 2 mM - 60 mM, 2, 5 mM - 60 mM, 3 mM - 60 mM, 4 mM - 60 mM, 5 mM - 60 mM, 6 mM - 60 mM, 8 mM - 60 mM, 10 - 60 mM, 20 - 60 mM, 30 - 60 mM, or 40 - 60 mM NAM.
  • the medium comprises 6 mM - 60 mM NAM. In some embodiments, the medium comprises 15 mM - 20 mM NAM. In some embodiments, the medium comprises about 1 mM - 20 mM NAM, such as about 2 mM - 20 mM, 2.5 mM - 20 mM, 3 mM - 20 mM, 4 mM - 20 mM, 5 mM - 20 mM, 6 mM - 20 mM, 8 mM - 20 mM, or 10 - 20 mM NAM. In some embodiments, the medium comprises 6 mM - 20 mM NAM.
  • the medium comprises nicotinic acid (NA) or a salt thereof and nicotinamide (NAM) or a salt thereof.
  • NA nicotinic acid
  • NAM nicotinamide
  • the medium comprises at least about 1 mM NA, such as at least about 1.5 mM, 2 mM, 2.5 mM, 3 mM, 4 mM, 5 mM, 6 mM, 8 mM, 10 mM, 12 mM, 14 niM, 16 mM, or 18 mM NA.
  • the medium comprises at least about 6 mM NA.
  • the medium comprises about 1 mM - 60 mM NA, such as about 2 mM - 60 mM, 2.5 mM - 60 mM, 3 mM - 60 mM, 4 mM - 60 mM,
  • the medium comprises 6 rnM - 60 mM NA. In some embodiments, the medium comprises 15 mM - 20 mM NA.
  • the medium comprises about 1 mM - 20 mM NA, such as about 2 mM - 20 mM, 2.5 rnM - 20 mM, 3 mM - 20 mM, 4 mM - 20 mM, 5 mM - 20 mM, 6 rnM - 20 mM, 8 mM - 20 mM, or 10 - 20 mM NA.
  • the medium comprises 6 rnM - 20 mM NA.
  • the medium comprises at least about 1 mM NAM, such as at least about 1.5 rnM, 2 rnM, 2,5 rnM, 3 rnM, 4 mM, 5 mM, 6 mM, 8 mM, 10 mM, 12 mM, 14 mM, 16 mM, or 18 mM NAM. In some embodiments, the medium comprises at least about 6 mM NAM.
  • the medium comprises about 1 mM - 60 mM NAM, such as about 2 mM - 60 mM, 2.5 mM - 60 mM, 3 mM - 60 rnM, 4 mM - 60 mM, 5 mM - 60 rnM, 6 mM - 60 mM, 8 mM - 60 rnM, 10 - 60 mM, 20 - 60 mM, 30 - 60 mM, or 40 - 60 mM NAM.
  • the medium comprises 6 mM - 60 mM NAM.
  • the medium comprises 15 mM - 20 mM NAM.
  • the medium comprises about 1 mM - 20 mM NAM, such as about 2 mM - 20 mM, 2.5 mM - 20 mM, 3 mM - 20 mM, 4 mM - 20 mM, 5 mM - 20 mM, 6 mM - 20 mM, 8 mM - 20 mM, or 10 - 20 mM NAM. In some embodiments, the medium comprises 6 mM - 20 mM NAM.
  • the medium comprises at least about 1 mM NA, such as at least about 1.5 mM, 2 mM, 2.5 mM, 3 mM, 4 mM, 5 mM, 6 mM, 8 mM, 10 mM, 12 mM, 14 mM, 16 mM, or 18 mM NA and at least about 1 mM NAM, such as at least about 1.5 mM, 2 mM, 2.5 mM, 3 M, 4 M, 5 mM, 6 mM, 8 mM, 10 mM, 12 mM, 14 mM, 16 mM, or 18 mM NAM.
  • the medium comprises at least about 6 mM NA and at least about
  • the medium comprises about 1 mM - 60 mM NA, such as about 2 mM - 60 mM, 2.5 mM - 60 mM, 3 mM - 60 mM, 4 mM - 60 mM, 5 mM - 60 mM, 6 about 1 mM - 60 mM NAM, such as about 2 mM - 60 mM, 2.5 mM - 60 mM, 3 mM - 60 mM,
  • the medium comprises 6 mM - 60 mM NA and comprises 6 mM - 60 mM NAM. In some embodiments, the medium comprises 15 mM --- 20 mM NA and comprises 15 mM --- 20 mM NAM.
  • the medium comprises about 1 mM - 20 mM NA, such as about 2 mM - 20 mM, 2.5 mM - 20 mM, 3 rnM - 20 mM, 4 mM - 20 mM, 5 rnM - 20 mM, 6 mM - 20 mM, 8 rnM - 20 mM, or 10 - 20 mM NA and comprises about 1 mM - 20 mM NAM, such as about 2 rnM --- 20 rnM, 2.5 rnM --- 20 rnM, 3 rnM - 20 rnM, 4 mM - 20 mM, 5 rnM - 20 rnM, 6 mM - 20 mM, 8 rnM - 20 rnM, or 10 - 20 mM NAM.
  • the medium comprises 6 mM - 20 mM NA and comprises 6 rnM - 20 mM
  • the yeast cells are any of the yeast cells described herein.
  • the yeast cells are not genetically modified organisms (GMOs).
  • GMO is an organism that has had its DNA altered or modified in some way through genetic engineering.
  • a GMO may comprise a heterologous nucleotide sequence, or may have had a gene deleted, silenced, or mutated using genetic engineering techniques such as recombinant DNA or CRISPER.
  • a GMO is not an organism developed purely by traditional breeding techniques of selecting an organism with a desired phenoty pe.
  • the medium comprises a sugar.
  • the sugar can act as an energy source for the yeast to grow.
  • the sugar is sucrose, glucose, fructose, lactose, maltose, dextrose, ribose, galactose, or combinations thereof.
  • the sugar is sucrose, glucose, fructose, lactose, maltose, or galactose.
  • the sugar is sucrose.
  • the medium comprises molasses.
  • the medium comprises syrup, such as corn syrup.
  • the medium comprises dry malt extract.
  • the medium comprises 1 g/L - 150 g/L, dry malt extract, such as 50 g/L - 100 g/L, 100 g/L - 150 g/L, 1 g/L - 50 g/L, 10 g/L - 40 g/L, 15 g/L - 30 g/L, 15 g/L - 25 g/L, 50 g/L, 100 g/L, 120 g/L, or 20 g/L dry malt extract.
  • the medium comprises sugarcane or beet extract.
  • the medium has at least 3° Brix, such as at least 4°, 5°, 6°, 7°, 8°, 9°, or 10°.
  • the medium has 3° ⁇ 2Q° Brix, such as 4°-20°, 4°-15°, 4°-10°, or 8°-12° Brix.
  • One degree“Brix” is 1 gram of sucrose in 100 grams of solution.
  • the medium comprises dextrose, rihose, or dextrose and ribose.
  • the medium comprises 1 g/L - 50 g/L dextrose, such as 10 g/L - 40 g/L, 15 g/L - 30 g/L, 15 g/L - 25 g/L, or 20 g/L dextrose.
  • the medium comprises 1 g/L - 50 g/L ribose, such as 5 g/L - 40 g/L, 5 g/L - 30 g/L, 5 g/L - 20 g/L, 5 g/L ⁇ - 15 g/L or 10 g/L, ribose
  • the medium comprises a yeast nutrient.
  • Yeast nutrient may promote healthy growth of the yeast cells and may include, but is not limited to, diammomum phosphate (DAP); amino acids and/or proteins; vitamins and/or minerals such as biotin, pantothenic acid, calcium, magnesium, potassium, and zinc; yeast ghosts, yeast hulls, and/or inactivated yeast; or combinations thereof.
  • the yeast nutrient is a combination of diammomum phosphate, essential vitamins and co-factors, nitrogen (amino acids, proteins, and peptides) and minerals.
  • the medium comprises 100 pg/L - 500 pg/L yeast nutrient, such as 100 pg/L --- 400 pg/L, 150 pg/L --- 350 pg/L, 200 pg/L - 300 pg/L, 250 pg/L - 300 pg/L or 264 pg/L
  • the medium comprises a peptone.
  • the peptone is a soya peptone.
  • the medium comprises at least 1 g/L peptone, such as 1.1 g/L, 1.2 g/L, or 1.3 g/L peptone.
  • the medium comprises 1 g/L - 50 g/L peptone, such as 10 g/L - 40 g/L, 15 g/L - 30 g/L, 15 g/L - 25 g/L, or 20 g/L peptone.
  • the medium comprises biotin.
  • the medium comprises at least 100 pg/L biotin, such as at least 200 pg/L or 250 pg/L biotin.
  • the medium comprises between 250 pg/L and 300 pg/L biotin.
  • the medium comprise a flavonoid or a combination of flavonoids, such as 2 or 3 flavonoids.
  • A“flavonoid” is a compound having the general structure of a i 5-carbon skeleton, which consists of two phenyl rings and a heterocyclic ring.
  • flavonoids include, but are not limited to, anthocyanidms, such as malvidin, pelargondin, peoidin, and cyanidin; flavanols, such as catechin, epicatechin gallate, epigallocatechin, epigallocatechin gallate, proanthocyanidins, theaflavins, thearubigins, apiforol, and luteoforol; flavones, such as luteolin, apigenin, tangeritin, chrysin, and 6-hydroxyflavone; flavonols, such as quercetin and kaempferol, 3-hydroxyflavone, azaleatin, fisetm, galangin, gossypetm,
  • the flavonoid is fisetin, quercetin, apigenin, and luteolin.
  • the medium comprises quercetin. In some embodiments, the medium comprises fisetin. In some embodiments, the medium comprises quercetin and fisetin.
  • the medium comprises at least about 0.05 g/L, such as at least about 1 g/L, 1.5 g/L, 2 g/L, 2.5 g/L, 3 g/L, 3.5 g/L, or 4 g/L of a flavonoid or a combination of flavonoids. In some embodiments, the medium comprises at least about 4 g/L of a
  • the medium comprises 0.05 g/L - 10 g/L, such as 2 g/L - 8 g/L, 3 g/L- 7 g/L, 4 g/L-6 g/L of a flavonoid or a combination of flavonoids.
  • the medium comprises 10 mg/L - 100 mg/L fisetin, such as 20 mg/L - 90 mg/L, 25 mg/L - 80 mg/L, 30 mg/L - 70 mg/L, 30 mg/L - 50 mg/L, 50 mg/L- 70 mg/L, 30 mg/L, or 65 mg/L - 70 mg/L fisetin.
  • the medium comprises 10 mg/L - 100 mg/L quercetin, such as 20 mg/L - 90 mg/L, 25 mg/L - 80 mg/L, 30 mg/L - 70 mg/L, 30 mg/L - SO mg/L, 50 mg/L- 70 mg/L, 30 mg/L, or 65 mg/L - 70 mg/L quercetin.
  • 10 mg/L - 100 mg/L quercetin such as 20 mg/L - 90 mg/L, 25 mg/L - 80 mg/L, 30 mg/L - 70 mg/L, 30 mg/L - SO mg/L, 50 mg/L- 70 mg/L, 30 mg/L, or 65 mg/L - 70 mg/L quercetin.
  • the medium comprises a plant extract, a plant concentrate, or a plant powder. In some embodiments, the medium comprises a fruit or vegetable extract, a fruit or vegetable concentrate, or a fruit or vegetable powder. [0055] In some embodiments, the medium comprises ellagic acid, tryptophan, adenine, benfotiamine, thiamin, resveratroi, piperlongumine, vitamin B 2 , A-acetylcysteine, S ⁇
  • the medium comprises ellagic acid, tryptophan, adenine, benfotiamine, thiamin, resveratroi, or combinations thereof. In some embodiments, the medium comprises tryptophan, adenine, benfotiamine, thiamin, resveratroi, or combinations thereof. In some embodiments, the medium comprises piperlongumine, vitamin Eh, /V-acetyleysteine, Ladenosylmethionine (SAM), trimethylglycine, or combinations thereof. In some embodiments, the medium comprises piperlongumine.
  • the medium comprises adenine.
  • the medium comprises 500 pg/L, - 500 rng/L adenine, such as 750 pg/L - 400 mg/L, 1 mg/L - 300 mg/L, 1 rng/L - 200 mg/L, 4 mg/L - 150 mg/L, 4 mg/ L - 70 mg/L, or 65 rng/L --- 133 mg/L adenine.
  • the medium comprises benfotiamine. In some embodiments, the medium comprises benfotiamine.
  • the medium comprises 500 pg/L -1.5 mg/L benfotiamine, such as 600 pgL - 1.25 mg/L, 700 pg/L - 1 rng/L, 750 pg/L - 900 pg/L, or 800 pg/L benfotiamine.
  • the medium comprises thiamin. In some embodiments, the medium comprises 500 pg/L -500 mg/L thiamin, such as 1 rng/L --- 20 mg/L, 2 mg/L - 15 mg/L,
  • the medium comprises ellagic acid. In some embodiments, the medium comprises ellagic acid.
  • the medium comprises 1 rng/L - 30 mg/L ellagic acid, such as 1 mg/L - 20 rng/L, 2 mg/L - 15 rng/L, 2 mg/L - 10 mg/L, 3 mg/L --- 5 mg/L, or 3 mg/L ellagic acid.
  • the medium comprises resveratroi.
  • the medium comprises 10 mg/L - 1 g/L resveratroi, such as 30 mg/L - 800 mg/L, 40 rng/L - 600 mg/L, 50 mg/L - 500 mg/L, 60 mg/L - 450 mg/L, 65 mg/ L - 70 mg/L, or 350 mg/L - 450 mg/L resveratrol.
  • the medium comprises tryptophan.
  • the medium comprises 1 mg/L - 30 mg/L thiamin, such as 3 mg/L - 20 mg/L, 5 mg/1, - 15 mg/L, 10 mg/L - 15 mg/L, 10 mg/L - 11 mg/L, or 10.2 mg/L tryptophan.
  • the medium comprises a pH stabilizer. In some embodiments, the medium does not comprise a pH stabilizer. In some embodiments, the medium comprises 500 mg/L -1.5 g/L pH stabilizer, such as 600 mg/L - 1.25 g/L, 600 mg/L - 1 g/L, 600 mg/L - 800 mg/L, or 700 mg/L pH stabilizer.
  • the method comprising culturing yeast cells, such as any of the yeast cells described herein, in a medium described herein, such as a medium comprising NA and/or NAM.
  • the method comprises culturing yeast cells m a medium described herein. In some embodiments, the method comprises culturing yeast cells in a medium described herein and extracting one or more of NMN, NR, or NAD+ from the yeast cells.
  • the method comprises culturing the yeast cells at room temperature.
  • the temperature of the medium during culturing is about 75° F - about 85° F.
  • the method comprises culturing the yeast cells for at least about 1 hour, such as at least about 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 12 hours, 18 hours, 21 hours, 24 hours, 30 hours, 36 hours, 42 hours, 48 hours, or 60 hours.
  • the method comprises culturing the yeast cells for 1 hour-3 days, such as 1 hour-2 days, 2 hours-2 days, 2 hours- 1 day, or 3 hours- 1 day.
  • the culturing comprises stirring or aerating the medium.
  • the method further comprises adding one or more of yeast nutrient, soya peptone, or a sugar after at least 2 hours of culturing, such as after at least 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 1 1 hours, 12 hours or 18 hours.
  • the method further comprises adding one or more of yeast nutrient, soya peptone, or a sugar 2 hours - 20 hours after the culturing began, such as 3 hours - 20 hours, 4 hours - 20 hours, 5 hours - 20 hours, 6 hours - 20 hours, 7 hours - 20 hours, 8 hours - 20 hours, 9 hours --- 20 hours, 10 hours - 20 hours, 11 hours - 20 hours, or 12 hours - 20 hours after the culturing began
  • the method further comprises inactivating the yeast cells.
  • the inactivating comprises sonicating, microwaving, or pasteurizing the yeast cells.
  • the inactivating comprises sonicating the yeast cells.
  • the inactivating comprises sonicating the yeast cells using power ultrasound. Power ultrasound has been successfully used to inactivate microorganisms in fruit juices (Adekunte et a!., Food Chem, 2010, 122(3): 500-507).
  • the inactivating comprises heating the yeast cells to at least a temperature of 71.5 °C (160 7 °F) for at least 15 seconds.
  • the inactivating comprises heating the yeast cells to at least 135 °C (275 °F) for at least 1 second.
  • the inactivation comprises freezing with liquid nitrogen or freeze-drying.
  • the method further comprises concentrating the yeast cells.
  • the concentrating comprises filtering the yeast cells.
  • the filters used to concentrate the yeast cells can include, but are not limited to size-exclusion filters, such as ultrafiltration filters.
  • the concentrating comprises centrifuging the yeast cells.
  • the method further comprises drying the yeast cells.
  • the method further comprises freeze drying the yeast cells.
  • the method further comprises lysing the yeast cells to produce an extract.
  • the lysing is chemical or mechanical lysing.
  • the lysing is mechanical lysing.
  • the mechanical lysing is performed by grinding the yeast cells with rotating blades.
  • the lysing is homogenization or sonication.
  • the method further comprises purifying the extract.
  • the pH of the extract is less than about 7, such as less than about 6.5, 6, 5.5, or 5.
  • the method further comprises centrifuging or filtering the extract.
  • the purifying does not comprise chemically purifying the extract.
  • the purifying does not comprise the addition of methanol, ethanol, or hazardous chemicals.
  • the method further comprises freeze drying the extract. In some embodiments, the method further comprises freeze drying the liquid portion of the extract.
  • the method comprises; (a) culturing yeast cells, such as any of the yeast cells described herein, in a medium described herein, such as a medium comprising NA and/or NAM; (b) concentrating the yeast cells of (a); (c) lysing the yeast cells of (b) to form an extract; (d) centrifuging or filtering the extract of (c); and (e) freeze drying the liquid portion of the extract of (d).
  • a medium described herein such as a medium comprising NA and/or NAM
  • the method comprises (a) culturing yeast cells from a yeast strain in a medium comprising at least about 9 raM (e.g., at least about 20 tiiM) NA and/or at least about 9 rnM (e.g., at least about 20 mM) NAM; and (b) determining if the yeast cells grow in the medium.
  • a medium comprising at least about 9 raM (e.g., at least about 20 tiiM) NA and/or at least about 9 rnM (e.g., at least about 20 mM) NAM
  • the method comprises fa) culturing yeast cells from a yeast strain in a medium comprising 9 mM - 60 mM NA (e.g., 20 mM - 60 mM) NA and/or 9 mM - 60 mM NAM (e.g., 20 mM - 60 mM) NAM; and (b) determining if the yeast cells grow in the medium.
  • the method further comprises repeating step fa) and step (b) with a plurality of yeast strains.
  • step (a) and step (b) are repeated 1 , 2, 3, 4, 5, 10, 15, 20,
  • the medium comprises at least about 9 mM NA, such as at least about 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, 50 mM, 55 mM, or 60 mM NA.
  • the medium comprises about 9 mM - 60 mM NA, such as about 20 mM - 60 mM, 25 mM— 60 mM, 30 mM— 60 mM, 35 mM— 60 mM, 40 mM— 60 mM, 45 mM - 60 mM, or 50 mM - 60 mM, NA.
  • the medium comprises 9 mM - 30 mM NA. In some embodiments, the medium comprises 20 mM - 60 mM NA. In some embodiments, the medium comprises at least about 9 mM NAM, such as at least about 10 mM,
  • the medium comprises 9 mM - 30 mM NAM. In some embodiments, the medium comprises about 9 mM - 60 mM NAM, such as about 20 mM - 60 mM, 25 mM - 60 mM, 30 mM - 60 mM, 35 mM - 60 mM, 40 mM - 60 mM, 45 mM - 60 mM, or 50 mM - 60 mM, NAM.
  • the medium comprises 20 mM - 60 mM NA and 20 mM - 60 mM NAM. In some embodiments, the medium comprises 9 mM - 30 mM NA and 9 mM - 30 mM NAM
  • the method comprises (a) culturing yeast ceils from a yeast strain in a medium comprising 20 mM - 60 mM NA and/or 20 mM - 60 mM NAM; (b) determining if the yeast cells grow in the medium; and (c) determining the concentration of one or more of nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid riboside (NAR), nicotinamide adenine dinucleotide (NAD+), nicotinic acid adenine dinucleotide (NAAD), or nicotinic acid mononucleotide (NAMN) in the yeast cells or the medium after step (a).
  • nicotinamide mononucleotide NNN
  • NR nicotinamide riboside
  • NAR nicotinic acid riboside
  • NAD+ nicotin
  • the method comprises repeating step (c) with a plurality of yeast strains. In some embodiments, step (c) is repeated 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, 100, 500, or 1000 times. In some embodiments, step (c) comprises determining the concentration of NMN, NR, or NMN and NR in the yeast cells or the medium after step (a).
  • the method comprises (a) culturing yeast cells from a yeast strain in a medium comprising 9 mM - 30 mM NA and/or 9 mM - 30 mM NAM; (h) determining if the yeast cells grow in the medium; and (c) determining the concentration of one or more of nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid riboside (NAR), nicotinamide adenine dinucieotide (NAD+), nicotinic acid adenine dinucleotide (NAAD), or nicotinic acid mononucleotide (NAMN) in the yeast cells or the medium after step (a).
  • nicotinamide mononucleotide NNN
  • NR nicotinamide riboside
  • NAR nicotinic acid riboside
  • NAD+ nicotinamide
  • the method comprises repeating step (c) with a plurality of yeast strains. In some embodiments, step (c) is repeated 1 , 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, 100, 500, or 1000 times. In some embodiments, step (c) comprises determining the concentration of NMN, NR, or NMN and NR in the yeast cells or the medium after step (a).
  • the method comprises (a) culturing yeast cells from a yeast strain in a medium comprising 20 mM - 60 mM NA and/or 20 mM --- 60 mM NAM; (b) determining if the yeast cells grow in the medium; (c) determining the concentration of one or more of nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid riboside (NAR), nicotinamide adenine dinucieotide (NAD+), nicotinic acid adenine dinucieotide (NAAD), or nicotinic acid mononucleotide (NAMN) in the yeast celis or the medium after step (a); and (d) selecting a yeast strain that grows m the medium and whose yeast celis produce one or more of NMN, NR, NAR, NAD+, NAAD, or NAMN at
  • step (d) comprises selecting a yeast strain that grows in the medium and whose yeast cells produce NMN, NR, or NMN and NR at a desired level after step (a).
  • the desired level is an amount sufficient to produce a dry composition comprising an extract of the yeast cells comprising at least 0.1%, such as at least 0.2%, 0.5%, 0.8%, 1%, 1.5%, 1.8%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, or 9% of one or more of NMN, NR, NAR, NAD+, NAAD, or NAMN (w/w).
  • the desired level is an amount sufficient to produce a diy composition comprising the yeast ceils and 1 %- 10% of one or more of NMN, NR, NAR, NAD+, NAAD, or NAMN (w/w), such as 1%-10% NMN, 1%-10% NR (w/w), or 1%- 10% NMN (w/w) and 1%-10% NR (w/w).
  • the method comprises (a) culturing yeast cells from a yeast strain in a medium comprising 9 mM - 30 mM NA and/or 9 mM - 30 mM NAM; (h) determining if the yeast cells grow in the medium; (c) determining the concentration of one or more of nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid riboside (NAR), nicotinamide adenine dinucleotide (NAD+), nicotinic acid adenine dinucleotide (NAAD), or nicotinic acid mononucleotide (NAMN) in the yeast cells or the medium after step (a); and (d) selecting a yeast strain that grows in the medium and whose yeast cells produce one or more of NMN, NR, NAR, NAD+, NAAD, or N AMN at a desired level
  • step (d) comprises selecting a yeast strain that grows in the medium and whose yeast cells produce NMN, NR, or NMN and NR at a desired level after step (a).
  • the desired level is an amount sufficient to produce a dry composition comprising an extract of the yeast cells comprising at least 0.1%, such as at least 0.2%, 0.5%, 0.8%, 1%, 1.5%, 1.8%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, or 9% of one or more of NMN, NR, NAR, NAD+, NAAD, or NAMN (w/w).
  • the desired level is an amount sufficient to produce a dry composition comprising the yeast ceils and 1 %- 10% of one or more of NMN, NR, NAR, NAD+, NAAD, or NAMN (w/w), such as 1%-10% NMN, 1%-10% NR (w/w), or S %- 10% NMN (w/w) and 1 %- 10% NR (w/w).
  • yeast cells are also provided herein.
  • the yeast cell is produced in a method described herein, such as a yeast cell produced in method of culturing yeast cells.
  • the yeast cell is from a yeast strain selected in a method of screening yeast cells discloses herein.
  • the yeast cells described herein are yeast cells that produce NMN and/or NR when cultured in a medium comprising NA and/or NAM.
  • the yeast ceils described herein are yeast cells that produce NAR, NAD+, NAAD, NAMN, or combinations thereof when cultured m a medium comprising NA and/or NAM.
  • the yeast cells described herein are yeast cells that produce NMN and/or NR in an amount sufficient to produce a dry' composition compri sing an extract of the yeast cells comprising 0.5%-10% NMN and/or NR (w/w) when cultured in a medium comprising NA and/or NAM.
  • the yeast cells are not genetically modified organisms (GMOs).
  • GMO is an organism that has had its DNA altered or modified in some way through genetic engineering.
  • a GMO may comprise a heterologous nucleotide sequence, or may have had a gene deleted, silenced, or mutated using genetic engineering techniques such as recombinant DNA or CRISPER.
  • a GMO is not an organism developed purely by traditional breeding techniques of selecting an organism with a desired phenotype.
  • the yeast cells are Saccharomyces (e.g., Saccharomyces cerevisiae). In some embodiments, the yeast cells are Kluyveromyces . In some embodiments, the yeast cells are Candida. In some embodiments, the yeast cells are not Candida. In some embodiments, the yeast cells are Pichia.
  • compositions comprising yeast cells or extracts thereof.
  • the yeast cells are any of the yeast cell disclosed herein, such as a yeast cell produced by a method described herein.
  • the yeast cells have been inactivated.
  • the yeast cells have been inactivated by sonication, microwaving, or pasteurization.
  • the composition has been dried.
  • the composition has been freeze dried.
  • the composition is a paste or powder
  • the composition is sterile.
  • Sterile pharmaceutical formulations are compounded or manufactured according to pharmaceutical-grade sterilization standards (United States Pharmacopeia Chapters 797, 1072, and 1211; California Business & Professions Code 4127 7; 16 California Code of Regulations 1751, 21 Code of Federal
  • the composition comprises at least 500 mM NR, such as at least 600 mM, 700 mM, 800 mM, 900 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, or 6 mM NR.
  • the composition comprises at least 500 mM NMN, such as at least 600 mM, 700 mM, 800 mM, 900 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, or 6 mM NMN.
  • the composition comprises at least 500 mM NAD+, such as at least 600 mM, 700 mM, 800 mM, 900 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, or 6 mM NAD+.
  • the composition comprises at least 500 mM NR, such as at least 600 mM, 700 mM, 800 mM, 900 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, or 6 mM NR and at least 500 mM NMN, such as at least 600 mM, 700 mM, 800 mM, 900 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, or 6 mM NMN.
  • 500 mM NR such as at least 600 mM, 700 mM, 800 mM, 900 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, or 6 mM NMN.
  • the composition comprises at least 500 m.M NR, such as at least 600 mM, 700 mM, 800 mM, 900 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, or 6 mM NR and at least 500 mM NAD+, such as at least 600 mM, 700 mM, 800 mM, 900 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, or 6 mM NAD+.
  • the composition comprises at least 500 mM NMN, such as at least 600 mM, 700 mM, 800 mM, 900 mM, 1 mM, 2 mM, 3 mM, 4 mM,
  • the composition comprises at least 500 mM NR, such as at least 600 mM, 700 mM, 800 mM, 900 mM,
  • the composition comprises one or more of: (a) 0.05% - 1% NAM, (b) 0.5% - 1.2% NA, (c) 0.05% - 0.23% NAD+, (d) 0.002% - 0.02% NADH, (e) 0.02% - 0.08% NADP+, (f) 0.01% - 0.2% NADPH, (g) 0.02% - 0.07% NMN, (h) 0.01% - 0.2% NAMN, (i) 0.001% - 0.009% NR, (j) 0.002%-0.Q15% NAR, (k) 0.0005%-0.004% MNA, and (1) 0.001%-0.02% tngonellme (w/w).
  • the composition comprises (a) 0.05% - 1% NAM, such as 0.06% - 1% NAM, 0.07% - 1% NAM, 0.08% - 1% NAM, or 0.09% - 1% NAM.
  • the composition comprises (b) 0.5% - 1.2% NA, such as 0.6% - 1.2% NA, 0.7% - 1.2% NA, 0 8% - 1.2% NA, 0.9% - 1.2% NA, 1 % - 1.2% NA, or 1.1% - 1.2% NA.
  • the composition comprises (c) 0.05% - 0.23% NAD+, such as 0.08% - 0.23% NAD+, 0 1% - 0.23% NAD+, 0.12% - 0.23% NAD+, 0.14% - 0 23% NAD+, 0.16% - 0.23% NAD+, or 0.2% - 0.23% NAD+.
  • the composition composes (d) 0.002% - 0 02% NADH, such as 0 005% - 0.02% NADH, 0.01% - 0.02% NADH, or 0.015% - 0.02% NADH.
  • the composition comprises (e) 0.02% - 0.08% NADP+, such as 0.02% - 0.08% NADP+, 0.04% - 0.08% NADP+, 0.06% - 0.08% NADP+, or 0 07% - 0.08% NADP+.
  • the composition comprises (f) 0.01% - 0.2% NADPH, such as 0.03% - 0.2% NADPH, 0.06% - 0.2% NADPH, 0.09% - 0.2% NADPH, 0.12% - 0.2% NADPH, or 0.15% - 0 2% NADPH.
  • the composition comprises (g) 0.02% - 0.07% NMN, such as 0.03% - 0.07% NMN, 0.04% - 0.07% NMN, 0.05% - 0.07% NMN, or 0.06% - 0.07% NMN.
  • the composition composes (h) 0.01% - 0.2% NAMN, such as 0.03% - 0.2% NAMN, 0.06% - 0.2% NAMN, 0.1% - 0.2% NAMN, or 0.1 5% - 0.2% NAMN.
  • the composition comprises (i) 0.001% - 0.009% N such as 0.003% - 0.009% NR, 0.005% - 0.009% NR.
  • the composition comprises (]) 0.002%-0.015% NAR, such as 0.005%-0.015% NAR. Q.008%-0.015% NAR, 0.01%-0.015% NAR, or 0.012%-0.015% NAR
  • the composition comprises (k) 0.0005%-0.004% IVINA, such as 0.001%- 0.004% AINA, 0.002%-0.004% MNA, or 0.003%-0.004% AINA.
  • the composition comprises (1) 0.001%-0.02% trigonelline, such as 0.005%-0.02% trigonelline, 0.0l%-0.02% trigonelline, or 0.015%-0.02% trigonelline.
  • the composition comprises a total amount of 0.1%-0.5% (w/ ' w) of NAD+, NMN, N MN, NR, and NAR. In some embodiments, the composition comprises a total amount of 0.5%-2.25% (w/w) of NAM, NA, NAD+, NMN, NAMN, NR, and NAR. In some embodiments, the composition comprises a total amount of 0. l%-0.6% (w/ ' w) of NAD+, NADH, NADP+, NADPH, NMN, NAMN, NR NAR, MNA, and trigonelline. In some embodiments, the composition comprises a total amount of 0.5%-2.26% (w/w) of NAM, NA,
  • the composition comprises at least 0.005% NR (w/w). In some embodiments, the composition comprises at least 0.5% NR (w/w) and/or at least 0.05 (e.g., 0.5%) NMN (w/w). In some embodiments, the composition comprises at least 0.005% NR (w/w) (e.g., 0.05% or 0.5% NR (w/w)), such as at least 1%, 1.5%, 1.8%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, or 9% NR (w/w).
  • the composition comprises at least 0 05 (e.g., 0 5%) NMN (w/w), such as at least 1%, 1.5%, 1 8%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, or 9% NMN (w/w).
  • the composition comprises at least 0.005% NR (w/w) (e.g., 0 05% or 0.5% NR (w/w)), such as at least 1%, 1.5%, 1 8%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, or 9% NR and comprises at least 0 05 (e.g., 0 5%) NMN (w/w), such as at least 1%, 1.5%, 1.8%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, or 9% NMN (w/w).
  • the composition comprises at least 0.5% NAR (w/w), such as at least 1%, 1.5%, 1.8%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, or 9% NAR (w/w).
  • the composition comprises at least 0.5% NAD+ (w/w), such as at least 1%, 1.5%, 1.8%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, or 9% NAD+ (w/w).
  • the composition comprises at least 0.5% NAAD (w/w), such as at least 1%, 1.5%, 1.8%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, or 9% NAAD (w/w).
  • the composition comprises at least 0.5% NAMN (w/w), such as at least 1%, 1.5%, 1.8%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, or 9% NAMN (w/w). In some embodiments, the composition comprises 0.5%-10% NAMN (w/w). In some embodiments, the composition comprises at least 1% NR (w/w) and at least 1% NMN (w/w). In some embodiments, the composition comprises at least 0.005% NR (w/w) (e.g., 0.05% NR (w/w)) and at least 1% NMN (w/w).
  • the composition comprises 0.01%-0.1% or 0.5%-10% NMN (w/w). In some embodiments, the composition comprises 0.001-0.0% or 0.5%-l0% NR (w/w). In some embodiments, the composition comprises 0.5% ⁇ 10% NAR (w/w). In some embodiments, the composition comprises Q.5%-10% NAD+ (w/w). In some embodiments, the composition comprises 0.5%-10% NAAD (w/w). In some embodiments, the composition comprises 0.5%-10% NAMN (w/w).
  • the composition comprises NR and the yeast cells produced at least 50% of the NR, such as at least 60%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 99%, or 100% of the NR
  • the compositi on comprises NR and the yeast cells produced 95% of the NR.
  • the composition does not comprise chemically synthesized NR.
  • 100% of the NR in the composition was either produced by the yeast cells or was produced by one or more other organisms, such as bacteria, plants, or animals.
  • 100% of the NR in the composition was either produced by the yeast cells or was produced by one or more other non-GMOs, such as bacteria, plants, or animals.
  • the composition comprises NR and the yeast cells produced 100% of the NR.
  • the composition comprises NMN and the yeast ceils produced at least 50% of the NMN, such as at least 60%, 70%, 75%, 80%, 85%, 90%, 95%,
  • the composition comprises NMN and the yeast cells produced 95% of the NMN .
  • the composition does not comprise chemically synthesized NMN.
  • 100% of the NMN in the composition was either produced by the yeast cells or was produced by one or more other organisms, such as bacteria, plants, or animals.
  • 100% of the NMN in the composition was either produced by the yeast cells or was produced by one or more other non- GMOs, such as bacteria, plants, or animals.
  • the composition comprises NMN and the yeast cells produced 100% of the NMN.
  • the composition composes NAD+ and the yeast ceils produced at least 50% of the NAD+, such as at least 60%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 99%, or 100% of the NAD+.
  • the composition comprises NAD+ and the yeast cells produced 95% of the NAD+.
  • the composition does not comprise chemically synthesized NAD+.
  • 100% of the NAD+ m the composition was either produced by the yeast cells or was produced by one or more other organisms, such as bacteria, plants, or animals.
  • 100% of the NAD+ in the composition was either produced by the yeast cells or was produced by one or more other non-GMOs, such as bacteria, plants, or animals.
  • the composition comprises NAD+ and the yeast cells produced 100% of the NAD+.
  • the composition comprises NAAD and the yeast cells produced at least 50% of the NAAD, such as at least 60%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 99%, or 100% of the NA AD.
  • the composition comprises NAAD and the yeast cells produced 95% of the NAAD.
  • the composition does not comprise chemically synthesized NA AD.
  • 100% of the NA AD in the composition was either produced by the yeast cells or was produced by one or more other organisms, such as bacteria, plants, or animals.
  • 100% of the N AAD in the composition was either produced by the yeast cells or was produced by one or more other non-GMOs, such as bacteria, plants, or animals.
  • the composition comprises NAAD and the yeast cells produced 100% of the NAAD.
  • the composition further comprises NA.
  • the composition comprises at least 0.5% NA (w/'w), such as at least 1%, 1.5%, 1.8%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, or 9% NA (w/w).
  • the composition comprises 0.5%-10% NA (w/w).
  • the composition further comprises a compound or plurality of compounds that are capable of lowering total plasma homocysteine in a subject.
  • examples of such compounds include, but are not limited to, serine, vitamin Be, vitamin B9, vitamin B12, and combinations thereof.
  • the composition comprises a flavonoid or a combination of f!avonoids, such as 2 or 3 flavonoids.
  • A“flavonoid” is a compound having the general structure of a 1 5-carbon skeleton, which consists of two phenyl rings and a heterocyclic ring.
  • flavonoids include, but are not limited to, anthoeyamdins, such as malvidm, pelargondin, peoidm, and cyanidin; flavanols, such as cateehm, epicatechm gal late, epigal!ocatechin, epigallocatechm gall ate, proanthocyanidins, theaflavins, thearubigms, apiforol, and luteoforol; fiavones, such as luteoim, apigenin, tangeritin, chrysin, and 6-hydroxyflavone; flavonols, such as quercetin and kaempferol, 3-hydroxyflavone, azaleatin, fisetin, galangin, gossypetin, kaempferide, isorhamnetin, morin, myricetin, natsudaidain, pachypodol, rhamnazin, rhamnetin; flavonone
  • the composition comprises fisetin. In some embodiments, the
  • composition comprises quercetin and fisetin.
  • the composition comprises at least 0.5% of a flavonoid or a combination of a flavonoid (w/w), such as at least 1 %, 1 .5%, 1.8%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, or 9% of a flavonoid or a combination of a flavonoid (w/w). In some embodiments, the composition comprises 0.5%-10% of a flavonoid or a combination of a flavonoid (w/w).
  • the composition further comprises a plant extract, a plant concentrate, or a plant powder.
  • the plant is bulgur, barely, rice, or combinations thereof.
  • the plant is tea.
  • the plant is green or black tea.
  • the medium comprises a fruit or vegetable extract, a fruit or vegetable concentrate, or a fruit or vegetable powder.
  • the fruit or vegetable is a broccoli, a cabbage, a cucumber, an edamame, an avocado, a tomato, a mushroom, a peanut, a pea, a squash, an asparagus, a potato, a lentil, a lima bean, or a combination thereof.
  • the composition further comprises tuna or an extract thereof, salmon or an extract thereof, bulgur or an extract thereof, barely or an extract thereof, or a combination thereof.
  • the composition comprises piperlongumme, vitamin B2, N- acetyleysteme, A-adenosylmethiomne (SAM), trimethylglycine, or combinations thereof.
  • SAM A-adenosylmethiomne
  • the composition is at least 50% pure NA, such as at least 60%, 70%, 80%, 90%, 95%, or 99% pure NA.
  • compositions comprising NMN, wherein the NMN was produced by yeast cells described herein. Also provided herein is a composition comprising NMN isolated from yeast cells described herein. In some embodiments, the composition is at least 50% pure NMN, such as at least 60%, 70%, 80%, 90%, 95%, or 99% pure NMN.
  • compositions comprising NAD+, wherein the NAD+ was produced by yeast cells described herein.
  • composition comprising NAD+ isolated from y3 ⁇ 4ast cells described herein. In some embodiments, the composition is at least 50% pure NAD+, such as at least 60%, 70%, 80%, 90%, 95%, or 99% pure NAD+.
  • compositions comprising the composition as described above and a pharmaceutically acceptable carrier, excipient, binder, or diluent.
  • the pharmaceutical compositions comprise one or more pharmaceutically acceptable excipients.
  • a pharmaceutically-acceptable excipient is a substance that is non-toxic and otherwise biologically suitable for administration to a subject. Such excipients facilitate administration of the compositions described herein and are compatible with the active ingredient. Examples of pharmaceutically-acceptable excipients include stabilizers, lubricants, surfactants, diluents, anti-oxidants, binders, coloring agents, bulking agents, emulsifiers, or taste-modifying agents.
  • pharmaceutical compositions according to the embodiments are sterile compositions. Pharmaceutical compositions may be prepared using compounding techniques known or that become available to those skilled in the art. Sterile compositions are also contemplated by the embodiments, including compositions that are in accord with national and local regulations governing such compositions.
  • compositions and compositions described herein may be formulated as solutions, emulsions, suspensions, dispersions, or inclusion complexes such as eyc!odextrins m suitable pharmaceutical solvents or carriers, or as pills, tablets, lozenges, bars, suppositories, sachets, dragees, granules, powders, powders for reconstitution, or capsules along with solid carriers according to conventional methods known m the art for preparation of various dosage forms.
  • Pharmaceutical compositions provided herein may be administered by a suitable route of delivery, such as oral, parenteral, rectal, nasal, or topical route, or by inhalation.
  • the compositions are formulated for intravenous or oral administration.
  • the pharmaceutical composition may be provided in a solid form, such as a tablet or capsule, or as a solution, emulsion, or suspension.
  • the pharmaceutical composition may be formulated to yield a dosage of the composition, e.g., from about 0.01 to about 20 mg/kg daily, or from about 20 to about 50 mg/kg daily or from about 50 to about 200 mg/kg daily.
  • Oral tablets may include the active
  • ingredient(s) mixed with compatible pharmaceutically acceptable excipients such as diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents.
  • suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like.
  • Exemplary liquid oral excipients include ethanol, glycerol, water, and the like.
  • Starch, polyvmyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and algmic acid are exemplar disintegrating agents.
  • Binding agents may include starch and gelatin.
  • the lubricating agent if present, may be magnesium stearate, stearic acid, or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating.
  • Capsules for oral administration include hard and soft gelatin capsules. To prepare hard gelatin capsules, active ingredients) may be mixed with a solid, semi-solid, or liquid diluent. Soft gelatin capsules may be prepared by mixing the active ingredient with water, an oil such as peanut oil or olive oil, liquid paraffin, a mixture of mono and di-glycerides of short chain fatty acids, polyethylene glycol 400, or propylene glycol.
  • Liquids for oral administration may be in the form of suspensions, solutions, emulsions, or syrups, or may be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like); non-aqueous vehicles, e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water; preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.
  • suspending agents for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethyl
  • compositions described herein may be formulated for rectal administration as a suppository.
  • parenteral use including intravenous, intramuscular, intraperitoneal, intranasal, or subcutaneous routes, the agents provided herein may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil.
  • Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride.
  • Such forms may be presented in unit-dose form such as ampoules or disposable injection devices, in multi-dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre-concentrate that can be used to prepare an injectable formulation.
  • Illustrative infusion doses range from about 1 to 2000 pg/kg/minute of the composition admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.
  • a pharmaceutical carrier for nasal, inhaled, or oral administration, the compositions or pharmaceutical compositions described herein may be administered using, for example, a spray formulation also containing a suitable carrier
  • compositions of the present embodiments are formulated as creams or ointments or a similar vehicle suitable for topical administration.
  • the pharmaceutical compositions described herein may be mixed with a pharmaceutical carrier at a concentration of about 0.1% to 1%, 1% to 5%, 5% to 10%, 10% to 20%, 20% to 30%, 0.1 % to 0 5%, 0 5% to 1%, 1% to 1.5%, 1.5% to 2%, 2% to 2 5%, 2.5% to 5%, 5% to 7 5%, or 7 5% to 10% of drug to vehicle.
  • Another mode of administering the compositions provided herein may utilize a patch formulation to affect transdermal delivery.
  • the pharmaceutical composition further comprises a matrix.
  • the matrix is a hydrophilic matrix, including, without limitation, non-ionic soluble cellulose ether (e.g., hydroxypropylmethylcellulose, hydroxypropylcellulose, and hydroxy lethylcellulose), non-ionic homopolymers of ethylene oxide (e.g., poly(ethylene oxide)), water soluble natural gums of polysaccharides (e.g., xanthum gum, alginate, and locust bean gum), water swellable, but insoluble, high molecular weight homopolymers and copolymers of acrylic acid optionally crosslinked with polyalkenyl alcohols, polyvinyl acetate, povidone mixture, cross-linked high amylose starch, and ionic methacrylate copolymers.
  • non-ionic soluble cellulose ether e.g., hydroxypropylmethylcellulose, hydroxypropylcellulose, and hydroxy lethylcellulose
  • the matrix is a hydrophobic matrix, including, without limitation, fatty acids, fatty acid esters, fatty alcohols, waxes of natural and synthetic origins with differing melting points, and hydrophobic polymers.
  • the hydrophobic matrix comprises stearic acid, lauryl, cetyl or cetostearyl alcohol, carnauba wax, beeswax, eandehlla wax,
  • the matrix is a lipid type matrix, biodegradable type matrix, or mineral type matrix.
  • the matrix is part of the outer layer of a tablet.
  • the wax matrix comprises a polymer.
  • the polymer is selected from acrylic polymer.
  • the pharmaceutical composition is formulated for extended release or slow release.
  • the pharmaceutical composition is formulated with a matrix.
  • the pharmaceutical composition is formulated with a wax matrix.
  • the wax matrix is vegetable-based.
  • the wax matrix comprises an acrylic polymer.
  • the present disclosure also relates to compositions in the form of a food product, a medical food product, or a dietary supplement.
  • a food product comprises a substance that can be used or prepared for use as food.
  • a food product may be in a solid or a liquid (e.g., beverage) form.
  • a food product may contain fruits, plants, vegetables, nuts, seeds, or juice, extracts, jam, concentrate, wheat, or alcohol thereof.
  • a food product may also contain milk, yogurt, meat, fish, or processed products thereof.
  • a food product may be flowers, leaves or bark of a plant. In some embodiments, the food product is kombucha.
  • a food product may be a product prepared from a natural food.
  • a food product may be a medical food, a functional food, a food additive or a nutritional food.
  • a medical food comprises foods that are specially formulated and intended for dietary management of a disease or condition that has distinctive nutritional needs that cannot be met by normal diet alone. Medical foods can be for oral ingestion or tube feeding.
  • a functional food comprises foods that have a potentially positive effect on health beyond basic nutrition.
  • a food additive comprises any substance added to food and its intended use results or may reasonably be expected to result, directly or indirectly, in its becoming a component or otherwise affecting the characteristics of any food. The addition of food additives may be during production, processing, treatment, packaging, or transportation or storage of food.
  • a nutritional food comprises foods that provide a high amount of nutrients. In some embodiments, the nutritional foods also comprise few calories.
  • a dietary supplement comprises a manufactured product intended to supplement the diet.
  • a dietary supplement can be synthetic or natural.
  • a dietary supplement can comprise one component or more than one component in combination.
  • a dietary supplement may comprise vitamins, amino acids, probiotics, minerals, fiber, fatty acids, pigments, polyphenols, lipids, or proteins.
  • the dietary supplement may be formulated as a pharmaceutical composition as discussed herein.
  • the dietary' supplement is intended to be taken by mouth as a pill, capsule, tablet, or liquid.
  • the dietary supplement comprises a label as being a dietary supplement.
  • the dietary supplement comprises non-dietary ingredients such as fillers, artificial colors, sweeteners, flavors, or binders.
  • the food product or dietary supplement comprises an effective amount of the composition for the treatment or prevention of a condition that can benefit from increased NAD+ level.
  • the condition is muscle performance deficiency, muscle growth deficiency, or mitochondrial disease.
  • the condition is aging.
  • kits comprising a plurality of yeast cells, a composition, a pharmaceutical composition, a dietary supplement, a food product, or a medical food described herein.
  • the kit is for use in a method described herein.
  • the kits comprises one or more containers comprising a plurality of yeast cells, a composition, a pharmaceutical composition, a dietary supplement, a food product, or a medical food described herein.
  • the kit and/or components of the kits are packaged, such as in packaging containing paper (e.g cardboard), plastic or other suitable material.
  • the kits are in suitable packaging.
  • Suitable packaging include, but is not limited to, vials, botles, jars, flexible packaging (e.g., sealed Mylar or plastic bags), and the like.
  • the components of the kit are contained in one or more containers.
  • the kit further comprises instructions for use in accordance with any of the methods described herein. Instructions supplied in the kits are typically written instructions on a label or package insert (e.g., a paper sheet included in the kit), but machine-readable instructions (e.g., instructions carried on a magnetic or optical storage disk) are also acceptable.
  • the present disclosure also relates to a method of modulating blood NAD+ level in a subject in need thereof.
  • the method comprises administering to the subject an effective amount of a composition, a pharmaceutical composition, a dietary supplement, a food product, or a medical food described herein.
  • the present disclosure also relates to a method of treatment or prevention of a disease or condition that can benefit from increased NAD+ levels, an anticancer or anti- inflammatory treatment, or an extend lifespan.
  • the method comprises administering to a subject in need thereof a therapeutically effective amount of a composition, a pharmaceutical composition, a dietary supplement, a food product, or a medical food described herein.
  • a composition, a pharmaceutical composition, a dietary supplement, a food product, or a medical food described herein is administered to a subject in need thereof.
  • the subject is a mammalian patient.
  • the subject is a human or an animal (e.g., cat, dog, cow, rat, mouse, horse, sheep, pig, goat, buffalo, chicken, duck, goose or other domesticated mammal).
  • the subject is a human patient.
  • a composition, a pharmaceutical composition, a dietary' supplement, a food product, or a medical food described herein is administered to an
  • the subject is a mammalian patient.
  • the subject is a human or an animal (e.g., mouse, rat, monkey, ape, worm, fly, fruit fly, fish, Zebrafish, frog, Xenopus, cat, dog, cow, pig, horse, sheep, goat, buffalo, chicken, duck, goose or other domesticated mammal).
  • mouse, rat, monkey, ape, worm, fly, fruit fly, fish, Zebrafish, frog, Xenopus, cat, dog, cow, pig, horse, sheep, goat, buffalo, chicken, duck, goose or other domesticated mammal e.g., mouse, rat, monkey, ape, worm, fly, fruit fly, fish, Zebrafish, frog, Xenopus, cat, dog, cow, pig, horse, sheep, goat, buffalo, chicken, duck, goose or other domesticated mammal.
  • the disease or condition to be treated or prevented using any of the compositions or methods described herein includes deficiency in muscle growth or muscle performance or a mitochondrial disease, including, but not limited to, aging, such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis; neurodegenerative disorders, such as Huntington’s disease, AIDS dementia complex, adrenoleukodystrophy, Alexander disease, Alper’s disease, Batten disease, Bovine spongiform encephalopathy, ataxia
  • telangiectasia Canavan disease, corticobasal degeneration, Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, Lyme disease, and multiple sclerosis; metabolic disorders, such as diabetes, obesity, insulin resistance, and a metabolic syndrome, or any combination thereof.
  • the mitochondrial disease or disorder is a neuromuscular disorder, a disorder of neuronal instability, a neurodegenerative disorder, or a mitochondrial myopathy.
  • the mitochondrial disease or disorder is Friedrich’s Ataxia, muscular dystrophy, multiple sclerosis, seizure disorders, migraine, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, ischemia, renal tubular acidosis, age-related neurodegeneration and cognitive decline, chemotherapy fatigue, frailty, age-related or chemotherapy-induced menopause or irregularities of menstrual cycling or ovulation, mitochondrial myopathies, mitochondrial damage (e.g., calcium accumulation, excitotoxicity, nitric oxide exposure, drug induced toxic damage or hypoxia), mitochondrial deregulation, Creutzfeldt-Jakob disease, dementia with Lewy bodies, fatal familial insomnia, multiple system atrophy, Huntington’s disease, Kennedy’s disease, frontotemporal lobar degeneration, Machado
  • myeimoclastic sclerosis myeimoclastic sclerosis, Refsum disease, spinocerebellar ataxia, tabes dorsalis, subacute combined degeneration of spinal cord, Tay-Sachs disease, transmissible spongiform
  • encephalopathy encephalopathy, wobbly hedgehog syndrome, toxic encephalopathy, Barth syndrome, beta- oxidation defects, carnitme-acyl- carnitine deficiency, carnitine deficiency, creatine deficiency syndrome, co-enzyme Q10 deficiency, complex I deficiency, complex II deficiency, complex III deficiency, complex IV deficiency, complex V deficiency, chronic progressive external ophthalmoplegia syndrome, CPT I deficiency, CPT IT deficiency, Kearns-Sayre syndrome, lactic acidosis, leukodystrophy, Leigh disease, Lucas disease, mitochondrial encephalomyopathy lactic acidosis and strokelike episodes (MELAS), progeria, Cockayne syndrome, myoclonic epilepsy and ragged-red fiber disease (MERRF), mitochondrial recessive ataxia syndrome, mitochondrial cytopathy, mitochondrial DNA depletion, mitochondrial encephal
  • myoneurogastrointestinal disorder and encephalopathy neuropathy, ataxia, and retinitis pigmentosa, Pearson syndrome, pyruvate carboxylase deficiency, pyruvate dehydrogenase deficiency, POLG2 mutations, encephalopathy and possibly liver disease or cardiomyopathy, acyl-CoA dehydrogenase deficiency, chrome traumatic encephalopathy (CTE), cancer, cachexia, infections caused by Hepatitis A, B, and/or C Virus, Human Immunodeficiency Virus (HIV), Human Papilloma Virus, human T-cell leukemia-lymphoma viruses (HTLV) or any combination thereof or any of their medical sequelae.
  • HIV Human Immunodeficiency Virus
  • HTLV human T-cell leukemia-lymphoma viruses
  • the disease is a disease associated with dementia.
  • the disease associated with dementia is selected from the group consisting of Alzheimer’s disease, vascular dementia, dementia with Lewy bodies (DLB), Parkinson’s disease, frontotemporal dementia, Creutzfeldt-Jakob disease, Normal pressure hydrocephalus, Huntington’s disease and Wernicke-Korsakoff syndrome, and any combination thereof.
  • the disease is a disease associated with deficient cognitive performance.
  • the disease is anxiety, depression, memory' loss, or PTSD.
  • the present disclosure provides methods for maintaining or enhancing muscle performance or muscle growth in a subject.
  • Muscle performance may include, without limitation, the capacity of a muscle or a group of muscles to generate forces to produce, maintain, sustain and modify postures and movements that are prerequisite to functional activity.
  • the method maintains or enhances muscle strength, muscle endurance, speed, muscle power, maximum muscle length, or oxygen level in muscle.
  • the method maintains muscle performance after or during physical labor or exercise. In some embodiments, the method reduces muscle fatigue, muscle sourness, or muscle tension after physical labor or exercise. In some embodiments, the method reduces the muscle reaction time after stimulation. In some embodiments, the method increases muscle mass or mitochondrial mass m muscle. In some embodiments, the method maintains or increases the number of myofibrils and rate of protein synthesis. In some embodiments, the method reduces inflammator response or oxidative stress m muscle. In some embodiments, the subject has a deficiency in muscle performance or muscle growth. In some embodiments, the subject does not have a deficiency in muscle performance or muscle growth.
  • the present disclosure is also directed to a method of extending lifespan.
  • the method maintains or enhances the healthspan in a subject with respect to body-mass index, physical performance, cardiac health, sexual performance, mental health, diet, or substance uses.
  • Physical performance may include athletic performance and general fitness. Physical performance may refer to the capacity to complete daily round of activities with enough energy left for recreation and relaxation.
  • Cardiac health may include health of the heart and blood vessels.
  • Mental health may include emotional, psychological, and social well-being.
  • a medium for culturing yeast cells comprising at least about 6 mM nicotinic acid (NA) or a salt thereof.
  • the medium of embodiment 1 comprising about 6 mM - 20 mM NA.
  • the medium of embodiment 3 or 4 comprising about 6 mM - 20 mM NAM.
  • a medium for culturing yeast cells comprising at least about 6 mM nicotinamide (NAM) or a salt thereof.
  • the medium of embodiment 6, comprising about 6 mM - 20 mM NAM.
  • the medium of embodiment 8, comprising at least about 6 mM of NA.
  • yeast cells are not genetically modified organisms (GMOs).
  • a method of screening a yeast strain comprising (a) culturing yeast cells from a yeast strain in a medium comprising 20 mM - 60 mM NA and/or 20 mM - 60 mM NAM; and (b) determining if the yeast cells grow in the medium.
  • nicotinamide mononucleotide NPN
  • NR nicotinamide riboside
  • NAR nicotinic acid riboside
  • NAD+ nicotinic acid adenine dinucleotide
  • NAAD nicotinic acid adenine dinucleotide
  • NAMN nicotinic acid mononucleotide
  • step (c) The method of embodiment 21 , further comprising repeating step (c) with a plurality of yeast strains.
  • a method of culturing yeast cells comprising culturing yeast cells in the medium of any one of embodiments 1-18.
  • a method of preparing NMN and/or NR comprising culturing yeast cells in the medium of any one of embodiments 1-18.
  • yeast cells are Saecharomyees cerevisiae
  • yeast cells are not genetically modified organisms (GMOs).
  • GMOs genetically modified organisms
  • a composition comprising the yeast cells produced by the method of any one of embodiments 28-42 or 45, or an extract thereof, or the extract of any one of embodiments 43 or 46-48.
  • a composition comprising yeast cells or an extract thereof comprising at least 500 mM NR and/or at least 500 m.M NMN.
  • a composition comprising yeast cells or an extract thereof comprising at least 0.4% NR (w/w) and/or at least 0.4% NMN (w/w).
  • composition of embodiment 51 comprising at least 0.4% NR (w/w) and at least 0.4% NMN (w/w).
  • composition of embodiment 56 wherein the composition comprises at least 0.25% NAD+.
  • composition of embodiment 59 wherein the composition comprises at least 1% NA (w/w).
  • composition of any one of embodiments 50-60 further comprising a compound or plurality of compounds that are capable of lowering total plasma homocysteine in a subject.
  • composition of embodiment 63, wherein the flavonoid is fisetin, quercetin, apigemn, and luteolin.
  • composition of embodiments 63 or 64 comprising quercetin, fisetin, or quercetin and fisetin
  • piperlongumine vitamin B2, N-acetylcysteine, S-adenosylmethionine (SAM), trimethylglycine, or combinations thereof.
  • SAM S-adenosylmethionine
  • composition of any one of embodiments 50-66 further comprising a fruit or vegetable extract, a fruit or vegetable concentrate, a fruit or vegetable powder, tuna or an extract thereof, salmon or an extract thereof, bulgur or an extract thereof, barely or an extract thereof, or a combination thereof.
  • composition of any one of embodiments 50-67, wherein the yeast cells have been inactivated is any one of embodiments 50-67, wherein the yeast cells have been inactivated.
  • a pharmaceutical composition comprising the composition of any one of embodiments 50-71 and a pharmaceutically acceptable excipient.
  • a dietary' supplement, food product, or medical food comprising the composition of any one of embodiments 50-71 or the pharmaceutical composition of embodiment 72.
  • a method of modulating blood NAD+ level comprising administering to a subject an effective amount of the composition of any of embodiments 50-71 , the pharmaceutical composition of embodiment 72, or the dietary supplement, food product, or medical food of embodiment 73.
  • a method of extending lifespan of a subject comprising administering to the subject an effective amount of the composition of any of embodiments 50-71, the pharmaceutical composition of embodiment 72, or the dietary supplement, food product, or medical food of embodiment 73
  • a method of improving healthspan of a subject comprising administering to the subject an effective amount of the composition of any of embodiments 50-71 , the pharmaceutical composition of embodiment 72, or the dietary supplement, food product, or medical food of embodiment 73.
  • a method of enhancing or maintaining muscle growth or performance comprising administering to a subject an effective amount of the composition of any of embodiments 50-71, the pharmaceutical composition of embodiment 72, or the dietary supplement, food product, or medical food of embodiment 73.
  • a method of treating or preventing a mitochondrial disease or condition comprising administering to a subject in need thereof a therapeutically effective amount of the composition of any of embodiments 50-71, the pharmaceutical composition of embodiment 72, or the dietary supplement, food product, or medical food of embodiment 73.
  • Example 1 Culture yeast in a medium comprising nicotinic acid [0132] Purpose: to produce NAD+ precursors such as NMN and NR from yeast by culturing the yeast in the presence of nicotinic acid
  • the flask was aerated on a stir plate at a rate of approximately 1000 rpm for 30 mins.
  • the pH was measured at 5.5, the Brix was 10°, the measured specific gravity' (SG) was 1.04 and the temperature was 79 °F ( ⁇ 26.1 °C), yielding a calibrated SG of 1.0423.
  • Saccharomyces cerevisiae (1 PUREPITCH® yeast culture (lot# 1059235)) was added to the medium and was mixed on a stir plate with aeration at a rate of 600 rpm for 3 hours. Cells were counted using a hemocytometer. A sample of the medium with yeast cells was diluted 8 fold with 1 % methylene blue. The final pH was 5.5 and the average cell count was 14. After an additional 2.5 hours of culturing, a sample was again taken. The pH was 4 and the average cell count was 29.7. The sample comprised a mixture of intact (blue) and living
  • the sample was then heated to 160 °F (-71.1 °C) for 15 minutes to inactivate the yeast.
  • the sample was then cooled in a refrigerator 2 hrs and then centrifuged at 3000 rpm for 10 min.
  • the liquid (4.5 cups or ⁇ IL) was then freeze dried.
  • the final pH was 3 and the procedure yielded 28.4 g of freeze dried extract with a crysta!ly, sticky, and fluffy texture.
  • the freeze dried extract was then analyzed by HPLC to determine the percent concentration of NMN and NR.
  • the final product was determined to contain 2.044% NMN and 0.53% NR.
  • NAD+ precursors such as NMN and NR from yeast by culturing the yeast in the presence of nicotinic acid, quercetin, and fisetin.
  • the flask was aerated on a stir plate at a rate of approximately 1000 rpm for 30 mins.
  • the pH was measured at 5.5, the Brix was 10°, the measured specific gravity (SG) was 1.04 and the temperature was 79 °F (-26.1 °C), yielding a calibrated SG of 1.0423.
  • Saccharomyces cerevisiae (1 PUREPITCH® yeast culture (lot# 1059235)) was added to the medium and was mixed on a stir plate with aeration at a rate of 600 rpm for 3 hours. Cells were counted using a hemocytometer. A sample of the medium with yeast cells was diluted 8 fold with 1% methylene blue. The final pH was 5.5 and the average cell count was 29. After an additional 2.5 hours of culturing, a sample was again taken. The pH was 5 and the average cell count was 46.7. The sample comprised yellow string/crystalline rods and the cells did not stain blue. [0140] After a 21.5 total hours of culturing, the medium was removed and the yeast cells (50 oz.
  • the sample was then heated to 160 °F (-71.1 °C) for 15 minutes to inactivate the yeast.
  • the sample was then cooled in a refrigerator 2 hrs and then centrifuged at 3000 rpm for 10 min.
  • the liquid (4 cups or -0.95 L) was then freeze dried.
  • the final pH was 3 and the procedure yielded 35.2 g of freeze dried extract that was yellow with a flaky and crystally texture.
  • the freeze dried extract was then analyzed by HPLC to determine the percent concentration of NMN and NR.
  • the final product was determined to contain 1.460% NMN and 3.008% NR
  • M AD+ precursors such as NMN and NR from yeast by culturing the yeast in the presence of nicotinic acid, sugar, and molasses.
  • the flask was aerated on a stir plate at a rate of approximately 1000 rpm for 30 mins.
  • the pH was measured at 6, the Brix was 4°, the measured specific gravity (SG) was 1.015 and the temperature was 79 °F (-26.1 °C), yielding a calibrated SG of 1.0173.
  • Saccharomyces cerevisiae (1 PUREPITCH® yeast culture (lot# 1059235)) was added to the medium and was mixed on a stir plate at a rate of 600 rpm for 3 hours. Cells were counted using a hemocytometer. A sample of the medium with yeast cells was diluted 8 fold with 1% methylene blue. The final pH was 6 and the average cell count was 63.3. After an additional 2,5 hours of culturing, a sample was again taken. The pH was 5.75 and the average cell count was 102.33. The sample comprised cells that formed large irregular clumps and all cells were stained blue.
  • the sample was then heated to 160 °F (-71.1 °C) for 15 minutes to inactivate the yeast.
  • the sample was then cooled in a refrigerator 2 hrs and then centrifuged at 3000 rpm for 10 min.
  • the liquid (3 cups or -0.7 L) was then freeze dried.
  • the final pH was 5.5 and the procedure yielded 5.1 g of freeze dried extract that was extremely sticky and had a caramel texture.
  • the freeze dried extract was then analyzed by HPLC to determine the percent concentration of NMN and NR The final product was determined to contain 1.635% NMN and 1 096% NR.
  • Example 4 Culture yeast in a medium comprising nicotinic acid, nicotinamide, quercetin, and fisetin
  • NAD+ precursors such as NMN and NR from yeast by culturing the yeast in the presence of nicotinic acid, nicotinamide, quercetin, and fisetin.
  • Saccharomyces cerevisiae (1 PUREPITCH® yeast culture (lot# 1059235)) was added to the medium and was mixed on a stir plate at a rate of 600 rpm for 12 hours.
  • the additional yeast nutrient, soya peptone, and sugar were added, the culture began to form and was still foaming when the culturing was completed and the culture was placed in a refrigerator to cool overnight.
  • the culture was removed from the refrigerator.
  • the foam from the top of the culture was removed and the broth was poured off.
  • the yeast sediment and foam were combined and were blended in a VITAMIX® for 5 min at power level 10.
  • the sample was then heated to 160 °F ( ⁇ 7l .1 °C) for 1 5 minutes to inactivate the yeast.
  • the sample was then cooled in a freezer for 2 hrs and then centrifuged at 3000 rpm for 10 mm.
  • the liquid was then freeze dried the procedure yielded 55 g of freeze dried extract.
  • the freeze dried extract was then analyzed by HPLC to determine the percent concentration of NMN, NR, N R, NAD+, and NAMN.
  • the final product was determined to contain 0.498% NMN, 2.00% NR, and 0.517% NAD+. NAR and NAMN were not detected in the final product.
  • Example 5 Culture yeast in a medium comprising nicotinic add, nicotinamide, quercetin, and fisetin
  • NAD+ precursors such as NMN and NR from yeast by culturing the yeast in the presence of fisetin and higher concentrations of nicotinic acid, nicotinamide, and quercetin.
  • Saccharomyces cerevisiae (1 PUKEPITCH® yeast culture (lot# 1059235)) was added to the medium and was mixed on a stir plate at a rate of 600 rpm for 12 hours. 0.5 g yeast nutrient, 5 g soya peptone, and 10 g sugar (sucrose) were added and the culture was stirred and aerated for an additional 6.5 hours. The culture was placed in a refrigerator to cool overnight.
  • the culture was removed from the refrigerator. Any foam on the top of the culture was removed and the broth was poured off. The yeast sediment and foam were combined and were blended in a VITAMIN® for 5 min at power level 10. The sample was then heated to 160 °F (-71.1 °C) for 15 minutes to inactivate the yeast. The sample was then cooled in a freezer for 2 hrs and then centrifuged at 3000 rpm for 10 min. The liquid was then freeze dried the procedure yielded 54 g of freeze dried extract. The freeze dried extract was then analyzed by HPLC to determine the percent concentration of NMN, NR, NAR, NAD+, and NAMN.
  • the final product was determined to contain 0.460% NMN, 4.960% NR, and 0.549% NAD+. NAR and NAMN were not detected in the final product.
  • the final product was a yellow flaky and fluffy powder. The lighter colored areas were sweet to the taste and darker brown areas were more bitter.
  • NAD+ precursors such as NMN and N from yeast by culturing the yeast in the presence of higher concentrations of nicotinic acid and nicotinamide.
  • Saccharomyces cerevisiae (1 PUREPITCH® yeast culture (lot# 1059235)) was added to the medium and was mixed on a stir plate at a rate of 600 rpm for 12 hours. 0.5 g yeast nutrient, 5 g soya peptone, and 10 g sugar (sucrose) were added and the culture was stirred and aerated for an additional 6.5 hours. The culture was placed m a refrigerator to cool overnight.
  • the culture was removed from the refrigerator. Any foam on the top of the culture was removed and the broth was poured off ’ .
  • the yeast sediment and foam were combined and were blended in a VET AMEX® for 5 min at power level 10.
  • the sample was then heated to 160 °F (-71.1 °C) for 15 minutes to inactivate the yeast.
  • the sample was then cooled in a freezer for 2 hrs and then centrifuged at 3000 rpm for 10 min.
  • the liquid was then freeze dried. The procedure yielded 50.5 g of freeze dried extract.
  • the freeze dried extract was then analyzed by HPLC to determine the percent concentration of NMN, NR, NAR, NAD+, and NAMN.
  • the final product was determined to contain 0.679% NMN, 5.890% NR, and 0.419% NAD+. NAR and NAMN were not detected in the final product.
  • the final product was a yellow flaky and fluffy powder.
  • Example 7 Culture yeast in different media
  • NAD+ precursors such as NMN and NR from yeast by culturing the yeast with or without niacin and nicotinamide, and with or without ellagic acid, tryptophan, and/or ribose.
  • Yeast extract, peptone, dextrose (YPD) base media was prepared by mixing distilled H 2 0, FERMAID® O (an autolyzed yeast nutrient with a high content of nitrogen and no diammonium phosphate (DAP)), nutritional yeast powder (STARWEST BOTANIC ALS®, product number 210205-51), peptone, dextrose, and pH stabilizer to create a final solution comprising 5 g/L FERMAID® O, 5 g/L nutritional yeast powder, 20 g/L peptone, 20 g/L dextrose, and 0.7 g/L pH stabilizer.
  • FERMAID® O an autolyzed yeast nutrient with a high content of nitrogen and no diammonium phosphate (DAP)
  • DAP diammonium phosphate
  • STARWEST BOTANIC ALS® product number 210205-51
  • peptone dextrose
  • pH stabilizer pH stabilizer
  • Dry malt extract-Ferm-0 (DME-FO) base media was prepared by mixing distilled H2O, dry malt extract (DME), and FERMAID® O to create a final solution comprising 120 g/L dry malt extract and 0.40 g/L FERMAID® O.
  • an inoculant was prepared in either YPD base media or DME-FO base media by adding Saccharomyces cerevisiae (1 packet per 250 ml of base media of WLP001
  • Flasks F1 -F7 were inoculated with 50 ml of the YPD inoculant (to yield 750 ml total media) and flasks F8-F10 were inoculated with 50 ml of the DME-FO inoculant (to yield 750 ml total media).
  • the final yeast slurries were placed into silicone mold trays and placed in a -80 °C freezer. After freezing, the silicone molds were placed onto racks in a freeze dryer. The samples were dried over 18 hours. After drying, the samples were prepared for mass
  • NAD+ precursors such as NMN and NR from yeast by culturing the yeast and harvesting with centrifugation.
  • yeast extract, dextrose, and soya peptone were diluted in distilled H20 to a final concentration of 20 g/L dextrose, 20 g/L peptone, and 10 g/L yeast extract in a total of 2000 ml.
  • DME-FO base media was prepared by mixing H20 with dry malt extract and FERMAID® O to a final concentration of 120 g/L DME and 0 4 g/L FERMAID® O in a total of 2000 ml.
  • the base media were sterilized by autoclaving at 121 °C for 15 minutes.
  • the base media were allowed to cool and then placed in a 27 °C incubator.
  • Biotin (264 gg/L), niacin (1.19 g/L), nicotinamide (1 19 g/L), and ribose (10 g/L) were added to the YPD base media (flask F6-1 1).
  • Yeast nutrient (0.26 g/L), biotin (264 gg/L), and nicotinamide (1.19 g/L.) were added to the DME-FO base media (flask F8-11).
  • the media were incubated at 27 °C for 18 hours with shaking (150 rpm). After incubation, the samples were each distributed into three centrifuge bottles and the yeast were pelleted at 4000 rpm for 3 minutes. The supernatant was removed from each bottle. For each sample, one centrifuge bottle was used to test a no wash condition, one centnfuge bottle was used to test a single wash condition, and one centrifuge bottle was used to test a double wash condition. For the no wash condition, the pellet was resuspended in 100 ml of distilled water.
  • the pellet was resuspended in 250 ml of distilled water, vortexed for 30 seconds, then pelleted at 4000 rpm for 3 minutes. The one wash pellet was then resuspended in 100 ml of distilled water.
  • the pellet was resuspended in 250 ml of distilled water, vortexed for 30 seconds, then pelleted at 4000 rpm for 3 minutes followed by a repeat of the wash step with 250 ml of new distilled water. After pelleting again, the double wash pellet was then resuspended in 100 ml of distilled water.
  • All six resuspended pellets (100 ml for each of the 0 wash, 1 wash, and 2 wash conditions for each of the F6-11 and F8-1 1) were transferred to silicone mold trays and flash frozen by submersion in liquid nitrogen. The silicone molds were then stored at -80 °C. After storage, the molds were placed m a freeze dry er for a total of about 20 hours. The final product was homogenized by mechanical mixing with a seoopula.
  • Example 9 Yeast culture growth conditions
  • a yeast culture medium was prepared according to the method described for F6- 11 in the preceding Example 8. The prepared media were distributed into four flasks, and inoculated 1 :20 with inoculant at 10 ', lO 5 , or 10 2 cells/ml. For the 10 5 cells/ml condition, the incubation temperature was also adjusted from 27 °C to 30 °C for one experiment.
  • the experimental conditions (conditions 1 -4) are summarized in Table 5, below.
  • Example 10 Yeast culture with media additions [0179] Purpose: to produce NAD+ precursors such as NMN and NR from yeast by testing the effect of media additions, including fisetin, quercetin, thiamin, adenine, and henfotiamine.
  • NAD+ precursors such as NMN and NR from yeast by testing the effect of media additions, including fisetin, quercetin, thiamin, adenine, and henfotiamine.
  • YPD base media was prepared as discussed in Example 8. After autoclaving, the YPD base media was supplemented with 264 pg/L biotin, 1.19 g/L niacin, 1.19 g/L
  • Flasks 13 2-13.6 were each with one of fisetin (0.07 g/L; flask 13.2), adenine (0 004 g/L; flask 13.3), benfotiamine (0.8 mg/L; flask 13.4), thiamin (0 005 g/L; flask 13.5), or quercetin (0.03 g/L; flask 13.6).
  • the flasks were inoculated with inoculant containing Saccharomyces cerevisiae (WLP001 CALIFORNIA ALE YEAST®).
  • Adenine addition at 0.004 g/L was the only condition that increased the yield (not counting niacin and niacinamide).
  • NAD+ precursors such as NMN and NR from yeast by culturing the yeast with resveratrol, low glucose, lower niacin/nicotinamide, or without pH stabilizer.
  • the experimental flasks were inoculated with IQ 3 cells/mL Saccharomyces cerevisiae (WLP001 CALIFORNIA ALE YEAST®; 1 packet per 250 ml of inoculant). The flasks w3 ⁇ 4re then incubated at 27 °C for 18 hours with shaking (150 rpm). [0187] After incubation, samples were pelleted at 4000 rpm for 3 minutes, washed with 250 ml of water, repelleted at 4000 rpm for 3 minutes, and then resuspended in 50 ml of distilled water. Samples were frozen and freeze dried as discussed in the preceding examples.
  • pH stabilizer may be omitted.
  • YPD base media was prepared as discussed in Example 8 and, after autoclaving. supplemented with 264 pg/ml biotin, 1.19 g/L niacin, 1.19 g/L nicotinamide, 10 g/L ribose, and
  • the supplemented YPD base media was inoculated with Saccharomyces cerevisiae.
  • the inoculated sample was incubated at 27 °C with shaking (150 rpm).
  • Example 13 Yeast culture growth patters*
  • NAD+ precursors such as NMN and NR from yeast by culturing the yeast in the presence of resveratrol, adenine, quercetin, fisetin, benfotiamine, and/or thiamin.
  • F1-F9 were prepared.
  • YPD base media was prepared as discussed in Example 8 for experimental flasks F1-F8.
  • flask F9 7.5 g yeast extract, 15 g peptone, and 3.75 g dextrose were added to 700 mL H2O and the mixture was autoclaved. After autoclaving, the flasks were supplemented with the supplements as indicated in Table 1 1 , below.
  • CALIFORNIA ALE YEAST® (LN 1075337)) and shaken to homogeneity (1 packet per 200 ml). After mixing, a cell count revealed the inoculated YPD media contained approximately 5.34 x 10 8 total cells. 1 mL of the inoculated YTD media was added to each condition.
  • the media were incubated at 27 °C for 18 hours with shaking (150 rpm). After incubation, 5 mL was removed for cell count and pH measurements and the samples were each distributed into three centrifuge bottles and the yeast were pelleted at 4000 rpm for 3 minutes. The supernatant was removed from each bottle. For each sample, the pellet was resuspended in 50 ml of distilled water.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des milieux et des méthodes de culture de cellules de levure pour produire un ou plusieurs composés précurseurs et apparentés à NAD+. La présente invention concerne également des compositions comprenant des cellules de levure qui produisent un ou plusieurs composés précurseurs et apparentés à NAD+ et des procédés d'utilisation des compositions, susceptibles de procurer des avantages dans le traitement et la prévention de maladies mitochondriales et de prolonger la durée de vie.
PCT/US2019/059921 2018-11-05 2019-11-05 Compositions et méthodes de culture de cellules de levure Ceased WO2020097116A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862755969P 2018-11-05 2018-11-05
US62/755,969 2018-11-05

Publications (1)

Publication Number Publication Date
WO2020097116A1 true WO2020097116A1 (fr) 2020-05-14

Family

ID=69177189

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/059921 Ceased WO2020097116A1 (fr) 2018-11-05 2019-11-05 Compositions et méthodes de culture de cellules de levure

Country Status (1)

Country Link
WO (1) WO2020097116A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114099556A (zh) * 2020-08-25 2022-03-01 大江生医股份有限公司 富含烟酰胺单核苷酸的酵母粉、其制备方法及用途
KR20230120939A (ko) * 2022-02-10 2023-08-17 제너럴바이오(주) Nr 및 nad를 함유한 발효효모조성물 제조방법 및 상기 방법으로 제조된 발효효모조성물
EP4322932A4 (fr) * 2021-04-13 2025-01-15 Animal Biosciences, Inc. Formulations de dérivés d'acide nicotinique et de polyphénols flavonoïdes et leurs utilisations

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090202680A1 (en) 2004-02-10 2009-08-13 Charles Brenner Yeast strain and method for using the same to produce nicotinamide riboside
CN102134556A (zh) * 2010-01-27 2011-07-27 重庆凯林制药有限公司 用于培养谷胱甘肽生产性酵母的培养基组合物
EP2431480A2 (fr) * 2002-08-09 2012-03-21 The President and Fellows of Harvard College Méthodes et compositions pouvant augmenter la résistance au stress de cellules et d'organismes
EP2813566A1 (fr) * 2013-06-14 2014-12-17 Ormige SA Procédé d'incorporation d'un composé dans des cellules de levure vivantes
CN104611400A (zh) * 2014-11-25 2015-05-13 江南大学 一种辅酶再生与树脂原位萃取促进Colletotrichum lini ST-1对DHEA的羟化方法
WO2015069860A1 (fr) * 2013-11-06 2015-05-14 President And Fellows Of Harvard College Production biologique de précurseurs et d'analogues de nad
WO2017158132A1 (fr) * 2016-03-16 2017-09-21 Dsm Ip Assets B.V. Production microbienne de riboside d'acide nicotinique

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2431480A2 (fr) * 2002-08-09 2012-03-21 The President and Fellows of Harvard College Méthodes et compositions pouvant augmenter la résistance au stress de cellules et d'organismes
US20090202680A1 (en) 2004-02-10 2009-08-13 Charles Brenner Yeast strain and method for using the same to produce nicotinamide riboside
CN102134556A (zh) * 2010-01-27 2011-07-27 重庆凯林制药有限公司 用于培养谷胱甘肽生产性酵母的培养基组合物
EP2813566A1 (fr) * 2013-06-14 2014-12-17 Ormige SA Procédé d'incorporation d'un composé dans des cellules de levure vivantes
WO2015069860A1 (fr) * 2013-11-06 2015-05-14 President And Fellows Of Harvard College Production biologique de précurseurs et d'analogues de nad
CN104611400A (zh) * 2014-11-25 2015-05-13 江南大学 一种辅酶再生与树脂原位萃取促进Colletotrichum lini ST-1对DHEA的羟化方法
WO2017158132A1 (fr) * 2016-03-16 2017-09-21 Dsm Ip Assets B.V. Production microbienne de riboside d'acide nicotinique

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ADEKUNTE, FOOD CHEM, vol. 122, no. 3, 2010, pages 500 - 507
BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
FANG ET AL., TRENDS MOL. MED., vol. 23, 2017, pages 899
J. BIOI. CHEM., vol. 288, pages 25938
KAWAMURA ET AL., J. NUTR. SCI. VI AMINOL, vol. 62, 2016, pages 272
KULIKOVA ET AL., J. BIO. CHEM., vol. 290, 2015, pages 27124
LU S.-P. ET AL: "Assimilation of Endogenous Nicotinamide Riboside Is Essential for Calorie Restriction-mediated Life Span Extension in Saccharomyces cerevisiae", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 284, no. 25, 19 June 2009 (2009-06-19), pages 17110 - 17119, XP055371390, ISSN: 0021-9258, DOI: 10.1074/jbc.M109.004010 *
MARINESCU ET AL., NATURE SCIENTIFIC REPORTS, vol. 8, 2018, pages 12278
MILLS ET AL., CELL METAB., vol. 24, 2016, pages 795
NIKIFOROV ET AL., J. BIOL. CHEM., vol. 286, 2011, pages 21767
SOCIALI ET AL., ONCOTARGET, vol. 7, 2016, pages 2968

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114099556A (zh) * 2020-08-25 2022-03-01 大江生医股份有限公司 富含烟酰胺单核苷酸的酵母粉、其制备方法及用途
US11833116B2 (en) 2020-08-25 2023-12-05 Tci Co., Ltd. Preparation method of yeast powder rich in nicotinamide mononucleotide, yeast powder, and methods for improving skin condition, hair health, antiinflammation, cardiovascular health, antioxidation, antiaging and/or relieving body fatigue
EP4206328A4 (fr) * 2020-08-25 2024-10-09 TCI Co., Ltd Poudre de levure riche en nicotinamide mononucléotide, procédé de préparation s'y rapportant et application associée
AU2021330052B2 (en) * 2020-08-25 2024-11-21 Tci Co., Ltd. Yeast powder rich in nicotinamide mononucleotide, preparation method therefor, and application thereof
US12383488B2 (en) 2020-08-25 2025-08-12 Tci Co., Ltd. Methods for improving skin condition, hair anti-inflammation activity, cardiovascular health, anti-oxidation activity, anti-aging activity, and/or relieving body fatigue by using yeast powder rich in nicotinamide mononucleotide
EP4322932A4 (fr) * 2021-04-13 2025-01-15 Animal Biosciences, Inc. Formulations de dérivés d'acide nicotinique et de polyphénols flavonoïdes et leurs utilisations
KR20230120939A (ko) * 2022-02-10 2023-08-17 제너럴바이오(주) Nr 및 nad를 함유한 발효효모조성물 제조방법 및 상기 방법으로 제조된 발효효모조성물
KR102821078B1 (ko) * 2022-02-10 2025-06-16 제너럴바이오(주) Nr 및 nad를 함유한 발효효모조성물 제조방법 및 상기 방법으로 제조된 발효효모조성물

Similar Documents

Publication Publication Date Title
US8822536B2 (en) Dietary supplements containing terpenoid acids of maslinic acid or oleanolic acid and process for enhancing muscle mass in mammals
WO2019212997A1 (fr) Compositions et procédés de préparation biosynthétique de composés d'urolithine et leur utilisation
WO2020097116A1 (fr) Compositions et méthodes de culture de cellules de levure
US20100210722A1 (en) Composition for preventing or treating lipid metabolic disorders comprising fucoxanthin or marine plant extract containing same
US20050089530A1 (en) Selenium yeast product, a method of preparing a selenium yeast product and the use of the product for preparing food, a dietary supplement or a drug
US20240000745A1 (en) Compositions and methods using a combination of oleuropein and quercetin for cellular energy
JP2018002604A (ja) ナチュラルキラー細胞の活性化剤
US20240009219A1 (en) Compositions and methods using a combination of oleuropein and nicotinamide riboside for cellular energy
TW201918251A (zh) 嗜粘蛋白阿克曼氏菌增殖材料
US20250009773A1 (en) Compositions and methods using a combination of oleuropein and vitamin b6
US20050180989A1 (en) Antihyperlipidemic agent and food
WO2021200216A1 (fr) Agent de renforcement musculaire
EP3266310B1 (fr) Composition nucléotidique et son application dans des produits alimentaires
AU2022225057A9 (en) Compositions and methods using a combination of oleuropein and magnesium
US20250319058A1 (en) Compositions and methods using a combination of fisetin and quercetin for cellular energy
US20250339455A1 (en) Compositions and methods using a combination of oleuropein and fisetin for cellular energy
JP7344661B2 (ja) 食品組成物の製造方法
CN113355253B (zh) 一种动物双歧杆菌及其应用
KR102660139B1 (ko) 단쇄 지방산을 포함하는 발효 생성물 및 그의 과체중 개선, 예방 또는 치료 용도
EP3947635A1 (fr) Composition pour supporter une fonction cérébrale saine
CN111494402A (zh) 一种兽用复合维生素的片剂及其制备方法
WO2022161485A1 (fr) Composition comprenant de la n-acétylglucosamine, son procédé de préparation et ses applications
CN101277617A (zh) 治疗肌肉萎缩的含甜菜碱的营养品
CA3269039A1 (fr) Compositions et procédés utilisant une association d'oleuropéine et de taurine
AU2023378254A1 (en) Compositions and methods using a combination of oleuropein and taurine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19839287

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19839287

Country of ref document: EP

Kind code of ref document: A1